

**(12) STANDARD PATENT  
(19) AUSTRALIAN PATENT OFFICE**

**(11) Application No. AU 2004291186 B2**

(54) Title **Triazine dimers for the treatment of autoimmune diseases**

(51) International Patent Classification(s)  
**C07D 251/70** (2006.01)      **C07D 403/14** (2006.01)  
**C07D 403/12** (2006.01)

(21) Application No: **2004291186**      (22) Date of Filing: **2004.11.22**

(87) WIPO No: **WO05/049607**

(30) Priority Data

(31) Number **60/524,021**      (32) Date **2003.11.24**      (33) Country **US**

(43) Publication Date: **2005.06.02**  
(44) Accepted Journal Date: **2012.01.19**

(71) Applicant(s)  
**Prometic Biosciences Inc.**

(72) Inventor(s)  
**Cameron, Alan D.;Groulx, Brigitte;Fortin, Daniel;Duceppe, Jean-Simon;Penney, Christopher;Wilb, Nicole;Ezzitouni, Abdallah;Zacharie, Boulos;Moreau, Nancie;Bienvenu, Jean-Francois;Abbott, Shaun D.;Gagnon, Lyne;Houde, Karine**

(74) Agent / Attorney  
**Shelston IP, Level 21 60 Margaret Street, Sydney, NSW, 2000**

(56) Related Art  
**Chemical Abstracts, Accession No. 1975:428204, published 1975  
EP 0310139 A2**

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date  
2 June 2005 (02.06.2005)

PCT

(10) International Publication Number  
WO 2005/049607 A1

(51) International Patent Classification<sup>7</sup>: C07D 403/14, 403/12, A61K 39/395, 31/53, A61P 37/00, A61M 1/36, C07K 1/22, 16/24

Lyne [CA/CA]; 1973 de la Victoire, Laval, Quebec H7M 3E5 (CA).

(21) International Application Number:  
PCT/CA2004/002003

(74) Agents: DUBUC, J. et al.; Goudreau Gage Dubuc, Stock Exchange Tower, 800 Place Victoria, Suite 3400, P.O. Box 242, Montreal, Quebec, H4Z 1E9 (CA).

(22) International Filing Date:  
22 November 2004 (22.11.2004)

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(25) Filing Language: English

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(26) Publication Language: English

Declaration under Rule 4.17:

— of inventorship (Rule 4.17(iv)) for US only

(30) Priority Data:  
60/524,021 24 November 2003 (24.11.2003) US

Published:

— with international search report  
— with amended claims and statement

(71) Applicant (for all designated States except US): PROMETIC BIOSCIENCES INC. [CA/CA]; 6100 avenue Royalmount, Montreal, Quebec H4P 2R2 (CA).

Date of publication of the amended claims and statement:  
14 July 2005

(72) Inventors; and

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(75) Inventors/Applicants (for US only): PENNEY, Christopher [CA/CA]; 12787 Joron, Pierrefonds, Quebec H8Z 3K7 (CA). ZACHARIE, Boulos [CA/CA]; 3202 Honoré de Balzac, Laval, Quebec H7P 5Y3 (CA). ABBOTT, Shaun, D. [CA/CA]; 9 de L'Eglise, Pointe-Claire, Quebec H9S 5J1 (CA). BIENVENU, Jean-François [CA/CA]; 4195 Stanislas, Laval, Québec H7R 6C9 (CA). CAMERON, Alan, D. [CA/CA]; 2264 Old Orchard, Montreal, Quebec H4A 3A8 (CA). DUCEPPE, Jean-Simon [CA/CA]; 118 McAndrew, St-Colomban, Quebec J5K 1K5 (CA). EZZITOUNI, Abdallah [CA/CA]; 1943 Chemin Nice, Laval, Quebec H7S 1G5 (CA). FORTIN, Daniel [CA/CA]; 265 Couture, Rosemère, Quebec J7A 2S2 (CA). HOUDE, Karine [CA/CA]; 7762 Lajeunesse, Montreal, Quebec H2R 2J4 (CA). MOREAU, Nancie [CA/CA]; 4195 Stanislas, Laval, Quebec H7R 6C9 (CA). WILB, Nicole [CA/CA]; 4865 Fulton, Montreal, Quebec H3W 1V2 (CA). GROUIX, Brigitte [CA/CA]; 5078 Fabre, Montreal, Quebec H2J 3W4 (CA). GAGNON,

WO 2005/049607 A1

(54) Title: TRIAZINE DIMERS FOR THE TREATMENT OF AUTOIMMUNE DISEASES

(57) Abstract: Compounds containing two mono- or disubstituted triazine rings covalently linked by an organic linker, but not linked directly to each other, may be used to treat autoimmune diseases. Autoimmune diseases which are amenable to treatment with compounds of this invention include rheumatoid arthritis, systemic lupus erythematosus (SLE), idiopathic (immune) thrombocytopenia (ITP), glomerulonephritis and vasculitis. The present invention also relates to reducing drug toxicity which often accompanies traditional therapies for autoimmune diseases. The compounds may also be used to bind antibody *in vitro* or *ex vivo*.

**COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS  
AND METHODS OF TREATMENT OF AUTOIMMUNE DISEASES  
USING SUCH COMPOUNDS**

5

**CROSS-REFERENCE TO RELATED APPLICATIONS**

This application claims the benefit of provisional U.S. Appln. No. 60/524,021, filed November 24, 2003.

**FIELD OF THE INVENTION**

10

The present invention relates to the treatment of autoimmune diseases with new organic compounds. These compounds contain two mono- or disubstituted triazine rings covalently linked by an organic linker, but not linked directly to each other.

**BACKGROUND OF THE INVENTION**

15

Any discussion of the prior art throughout the specification should in no way be considered as an admission that such prior art is widely known or forms part of common general knowledge in the field.

20

Autoimmune disease refers to any of a group of disorders or diseases in which tissue injury is associated with a humoral and/or cell-mediated immune response to body constituents or, in a broader sense, an immune response "to self". The pathological immune response may be systemic or organ specific. That is, for example, the immune response directed to self may affect joints, skin, the myelin sheath that protects neurons, kidney, liver, pancreas, thyroid, adrenals and ovaries. In fact, the list of autoimmune diseases is composed of more than eighty disorders. A few autoimmune diseases such as 25 vitiligo, in which patches of skin lose pigmentation, are merely annoying. Most others are debilitating, often progressive with time and eventually fatal. Systemic lupus erythematosus (SLE), for example, is a chronic disease in which 10-15% of patients die within a decade of diagnosis. In all but a few autoimmune diseases, the sex ratio skews towards women. For example, in SLE the ratio of female to male patients is nine to one. 30 In one particular case, Hashimoto's disease in which the immune system attacks the thyroid gland, the ratio is fifty to one.

It has long been known that immune complex formation plays a role in the etiology and progression of autoimmune disease. For example, in Goodman and Gilman's *The Pharmacological Basis of Therapeutics*, 16<sup>th</sup> Edition (1980), Macmillan

Publishing Co., on page 683, inflammation in patients with arthritis is stated to probably involve phagocytosis by leukocytes of complexes of antigen, antibody and complement – immune complexes. But it is only now being recognized that inflammation caused by immune complexes in the joints (arthritis), the kidneys 5 (glomerulonephritis) and blood vessels (vasculitis) is a major cause of morbidity in autoimmune diseases as noted by P.M. Hogarth *et al.*, Annual Reports in Medicinal Chemistry, 37, 217-224 (2002). Increased immune complex formation correlates with the presence of antibodies directed to self or so-called autoantibodies, and the presence 10 of the latter can also contribute to tissue inflammation either as part of an immune complex or unbound to antigen (free antibody). In some autoimmune diseases, the presence of free autoantibody contributes significantly to disease pathology. This has been clearly demonstrated for example, in SLE (anti-DNA antibodies), ITP (antibody response directed to platelets) and to a lesser extent rheumatoid arthritis (IgG reactive rheumatoid factor). The importance of the role of immune complexes and free 15 autoantibodies is further demonstrated by the fact that successful treatment of certain autoimmune diseases has been achieved by the removal of immune complexes and free antibody by specific immunoabsorption procedures. For example, the use of an apheresis procedure in which immune complexes and antibodies are removed by passage of a patient's blood through an immunoaffinity (Prosorba<sup>®</sup>) column was 20 approved by the U.S. FDA in 1987 for ITP and in 1999 for rheumatoid arthritis. Currently, however, there is no approved method for the treatment of autoimmune diseases which facilitates the elimination of immune complexes and autoantibodies by administration of a drug.

25 Another aspect of the etiology and progression of autoimmune disease is the role of proinflammatory cytokines. Under normal circumstances, proinflammatory cytokines such as tumor necrosis factor  $\alpha$  (TNF $\alpha$ ) and interleukin-1 (IL-1) play a protective role in the response to infection and cellular stress. But the pathological consequences which result from chronic and/or excessive production of TNF $\alpha$  and IL-1 30 are believed to underlie the progression of many autoimmune diseases such as rheumatoid arthritis, Crohn's disease, inflammatory bowel disease and psoriasis. Other proinflammatory cytokines include interleukin-6, interleukin-8, interleukin-17 and

granulocyte-macrophage colony stimulating factor. It appears, however, that TNF $\alpha$  is on the top of the proinflammatory cytokine cascade. That is, in terms of blocking one proinflammatory cytokine, blockage of TNF $\alpha$  would provide the maximum therapeutic effect. The ability of TNF $\alpha$  to downregulate other proinflammatory cytokines is reviewed by M. Feldmann in Perspectives, 2:364-371 (2002). Indeed, the impact of the antagonism of TNF $\alpha$  as a treatment option for arthritis, psoriatic arthritis, psoriasis and Crohn's disease has been illustrated by the U.S. FDA approval of Remicade (chimeric anti-TNF $\alpha$  monoclonal antibody), Enbrel (soluble TNF $\alpha$  p75 receptor fusion protein) and Humira (human anti-TNF $\alpha$  monoclonal antibody).

10

As may be inferred from the above discussion regarding the etiology and progression of autoimmune disease, its pathogenesis is complex and multifactorial. As such, there are a multitude of therapies available. But the majority of autoimmune diseases are poorly controlled by current treatments. Conventional treatments are not uniformly effective and are often associated with moderate to severe toxicity. Nonetheless, the above discussion indicates that there is a need for simple, well-defined organic compounds which can help the body eliminate immune complexes or at least prevent the deposition of circulating immune complexes and/or (simultaneously) inhibit the activity of TNF $\alpha$  while still being generally nontoxic to the patient. In summary, there is a need for an efficacious yet nontoxic treatment of chronic autoimmune disease.

20 The present invention provides compounds that are useful for the treatment of chronic autoimmune disease. Although not initially life-threatening, most autoimmune diseases are chronic conditions which slowly progress to a debilitating state. While numerous therapies are available, conventional treatments are not routinely efficacious. More problematic is the accompanying toxicity which often prohibits the long-term use necessary with a chronic disease. Current treatments for autoimmune disease can be broadly classified into two groups: those drugs which dampen or suppress the immune response to self and those drugs which address the symptoms that arise from chronic 30 inflammation. In greater detail, conventional treatments for autoimmune disease (e.g., primarily arthritis) are as follows:

1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): These include aspirin, ibuprofen, naproxen, etodolac and ketoprofen. NSAIDs are not relatively potent drugs and so are most commonly used as anti-inflammatory drugs in the early stages of disease (e.g., to relieve the pain and swelling which accompanies arthritis). But NSAIDs are associated with gastrointestinal irritation and liver toxicity. In order to address the gastrointestinal ulceration associated with the use of many NSAIDs, more selective NSAID drugs have been recently developed which selectively inhibit (Vioxx, Celebrex) or preferentially inhibit (Mobic) cyclooxygenase-2 (COX-2 inhibitors). COX-2 inhibitors, however, display untoward side effects which include gastrointestinal irritation, especially with longer-term use.
2. Corticosteroids: These include prednisone and dexamethasone. Corticosteroids are the most widely used anti-inflammatory agents for the treatment of rheumatoid arthritis. But they significantly increase the risk of osteoporosis, gastrointestinal toxicity and infection arising from generalized immune suppression. Therefore, corticosteroids tend to be used for the treatment of disease flares (e.g., SLE) and not as a chronic treatment.
3. Disease-Modifying Anti-Rheumatic Drugs (DMARDs): These include cytotoxic drugs such as methotrexate, azathioprine and cyclophosphamide, potent immunosuppressants such as cyclosporin A (Sandimmune, Neoral) and FK506 (tacrolimus) and a variety of other drugs such as hydrochloroquine and organogold salts (e.g., aurothioglucose). DMARDs are potent drugs and so can display significant efficacy in reducing inflammation and slowing the rate of disease progression. As such, physicians have traditionally used DMARDs as a second line of therapy after NSAIDs. As potent drugs, however, DMARDs have significant toxicity associated with their use. Cytotoxic drugs, for example, interfere with DNA replication which manifests itself with a number of toxic effects. The latter include bone marrow depression and subsequent risk of infection and neoplasia. The use of cyclosporin A and FK506 is limited by serious side effects which include renal and liver toxicities. Toxic effects associated with the use of hydrochloroquine include blindness, neuromyopathy and gastrointestinal distress. The most common side effect arising from therapy


with gold salts is dermatitis. But gold toxicity can also cause nephritis and bone marrow depression.

4. Biologicals: These include the recombinant proteins Remicade, Enbrel and  
5 Humira, all of which target TNF $\alpha$ , Kineret, which targets interleukin-1,  
Amevive, which targets T-cells (CD2 surface glycoprotein) and Raptiva which  
10 also targets T-cells (anti-CD11a antibody). But recombinant proteins and, in  
particular, recombinant antibodies are difficult to produce for widespread use and  
have toxic side effects associated with their use. Toxicities include potential  
15 immunological reactions, especially with the prolonged use that may be required  
for chronic conditions. In addition to the well-known HAMA (human anti-mouse  
antibody) response associated with chimeric or humanized antibodies, antibody  
mediated cytotoxicity mechanisms (ADCC and complement-mediated) may lead  
to side effects. More recently, it was discovered that antibodies, regardless of  
15 source or antigen specificity, can convert molecular oxygen into hydrogen  
peroxide and ozone as described by P. Wentworth *et al.* Science 293, 1806-1811  
(2001) and 298, 2195-2199 (2002). This could lead to cellular and tissue damage  
which may exacerbate treatment of an autoimmune condition with prolonged use.  
For example, it was shown that the production of hydrogen peroxide and ozone  
20 by antibodies could be linked to an inflammatory response in rats : a so-called  
Arthus reaction. The potent anti-TNF $\alpha$  activity of the antibody Remicade has led  
to increased risk of opportunistic infections which include tuberculosis,  
histoplasmosis, listeriosis and pneumocytosis.

25 Therefore, it is an objective of the present invention to provide novel compounds  
for use in treating autoimmune disease.

## SUMMARY OF THE INVENTION


According to a first aspect, the present invention provides a compound of the following formula:



5

wherein  $R_1$ ,  $R_2$ , and  $R_3$  are independently selected from the group consisting of

10




$C_{2-4}$  aminoalkyl, benzyl, and  $C_{2-4}$  hydroxyalkyl.

According to a second aspect, the present invention provides a compound 15 selected from the group consisting of:


## Compound No.

## Structure






1




5b




5c




5d






5f


17




18




19a




19b



20




21




5g


22




23




24



25




26




5h


27




28




29




30




5i









5j




5k






5m

49




50



and

51



According to a third aspect, the present invention provides a pharmaceutical composition comprising of at least one compound according to the first or second aspects, and a pharmaceutically acceptable carrier.

5 According to a fourth aspect, the present invention provides a method for treating a patient with glomerulonephritis, psoriasis, rheumatoid arthritis, and/or systemic lupus erythematosus comprising administering to said patient a therapeutically effective amount of a compound according to the first or second aspect, or a pharmaceutical composition of the third aspect.

10 According to a fifth aspect, the present invention provides a use of a compound according to the first or second aspect, for the manufacture of a medicament for treating a patient with glomerulonephritis, psoriasis, rheumatoid arthritis, and/or systemic lupus erythematosus.

15 According to a sixth aspect, the present invention provides a method of removal of human antibodies, comprising circulating blood or other physiological fluid through an apheresis column, wherein at least one compound according to the first or second aspects is covalently linked either directly or indirectly with an organic linker to an

insoluble support material which constitutes part of said apheresis column, such that at least some free antibodies and/or antibody-antigen immune complexes binds to the apheresis column.


According to a seventh aspect, the present invention provides a method of  
5 purification of antibodies, comprising:

- providing an insoluble support material to which at least one compound according to the first or second aspect is covalently linked either directly or indirectly with an organic linker;
- contacting antibodies with said at least one of said compound covalently linked to the insoluble support material, whereby at least some antibodies binds noncovalently to said at least one compound; and
- purifying the noncovalently bound antibodies.

According to a eighth aspect, the present invention provides an *in vitro* method of binding antibodies using at least one compound according to the first or second  
10 aspects, comprising incubating said at least one compound with antibodies under binding conditions, and then separating bound antibodies from free antibodies.

Unless the context clearly requires otherwise, throughout the description and the claims, the words "comprise", "comprising", and the like are to be construed in an inclusive sense as opposed to an exclusive or exhaustive sense; that is to say, in the  
15 sense of "including, but not limited to".

The present invention relates to a novel method for the treatment of chronic autoinunune disease, in particular arthritis and SLE, by administration of a compound to a mammal, preferably a human. Therefore, in accordance with this invention, certain mono-or disubstituted triazine dimers (in which one triazine monomer is connected to



the other by an organic linker) and their pharmaceutical compositions are provided which are able to facilitate the clearance of immune complexes or to limit their deposition within body organs such as kidney and/or to inhibit the proinflammatory actions of TNF $\alpha$ . In a preferred embodiment of this invention, these triazine compounds will affect both aspects of the inflammation process: immune complexes and TNF $\alpha$ . The therapeutic benefit resulting from this dual mechanism of action will manifest itself in terms of an improved toxicity profile. That is, the triazine compounds described in this invention are not potent inhibitors of TNF $\alpha$  nor will they completely eliminate immune complexes. TNF $\alpha$  does play a role in protection against infection while immune complexes play a role in feed-back mechanisms regulating immune responses (so-called idiopathic determinants). Therapeutic efficacy may result from the additive effect of the two mechanisms of action. Furthermore, toxicity due to chronic treatment and/or other drugs used in combination may be at least reduced or avoided.

In another embodiment of the present invention, the triazine compounds will affect only one aspect of the inflammation process. That is, these compounds will affect either immune complexes or TNF $\alpha$ . In the case where the triazine compounds influence the elimination of immune complexes or prevent their deposition, such compounds are expected to be particularly useful for the treatment of arthritis, systemic lupus erythematosus (SLE), idiopathic (immune) thrombocytopenia (ITP), glomerulonephritis and vasculitis. In the case where the triazine compounds inhibit TNF $\alpha$ , such compounds are expected to be particularly useful for the treatment of rheumatoid arthritis, psoriatic arthritis, psoriasis, Crohn's disease, inflammatory bowel disease, ankylosing spondylitis, Sjögren's syndrome, Still's disease (macrophage activation syndrome), uveitis, scleroderma, myositis, Reiter's syndrome and Wegener's syndrome. Of course, it is possible that some triazine compounds of this invention will affect the inflammation process by a biochemical mechanism which is in addition to and distinct from an effect on immune complexes and/or TNF $\alpha$ . But regardless of the mechanism(s) by which the triazine compounds affect the targeted autoimmune disease, it is an important aspect of this invention that said compounds do not potently affect any aspect of the inflammation process such that a deleterious toxicity will result.

Further aspects of the invention will be apparent to a person skilled in the art from the following description and claims, and generalizations thereto.

#### BRIEF DESCRIPTIONS OF THE DRAWINGS

5 Figure 1 illustrates a dose-response curve of compound 1 on the phagocytosis of immune complexes by RAW 264.7 macrophage-like cells.

10 Figures 2-3 illustrate the effect of compound 1 on NZBxNZW mice: mortality (Fig. 2) or proteinuria (Fig. 3). Fig. 3A illustrates mice with 5 g/L or more and Fig. 3B illustrates mice with improvement of kidney filtration.

15 Figure 4 illustrates the effect of compounds 1 and 9 on mortality of NZBxNZW mice:

20 Figure 5 illustrates the effect of compounds 1 and 20 on mortality of MRL/lpr mice.

Figure 6 illustrates the effect of compounds 1, 5 and 19a-20 on delayed-type hypersensitivity (DTH).

25 Figure 7 illustrates the effect of compounds 47, 51 and 49 on DTH.

Figure 8 illustrates the effect of compounds 1 and 19a on DTH.

25 Figure 9 illustrates the effect of compound 1 on collagen-induced arthritis.

Figure 10 illustrates the effect of compounds 1 and 19a on adjuvant-induced arthritis.


30 Figure 11 illustrates the effect of oral and intravenous administration of compounds 1 and 19a on adjuvant-induced arthritis.

Figure 12 illustrates the effect of oral and intravenous administration of compound **19a** on adjuvant-induced arthritis.


Figure 13 illustrates denaturing (sodium dodecyl sulfate or SDS) polyacrylamide gel electrophoresis (PAGE) of human total IgG bound and purified by compound **19b** linked to the resin: lane 1, prestained standards (broad range); lane 2, human total IgG; lane 3, flow through fraction; lane 4, wash fraction; and lane 5, eluted fraction.

#### DETAILED DESCRIPTION OF THE INVENTION

The present invention includes compounds, or pharmaceutically acceptable derivatives thereof, of the following general formula:



where  $A = -(CH_2)_n-$ ,  $n = 0, 1, 2, 3$  or  $-\overset{\text{CH}}{\underset{\text{CH}_3}{\text{CH}}}-$ ;



$Y, Y' = \text{CH}, \text{N}$   
 $Y$  is not necessarily equal to  $Y'$ ;


$C = -(CH_2)_n-$ ,  $n = 0, 1, 2, 3$  or  $-\overset{\text{CH}}{\underset{\text{CH}_3}{\text{CH}}}-$   
 $X = \text{NH}, \text{O}, \text{S};$

$R' = \text{hydrogen or } C_{1-4} \text{ alkyl, } C_{1-4} \text{ N-methylaminoalkyl or } N,N\text{-dimethylaminoalkyl};$

$A$  is not necessarily equal to  $C$ ;

and wherein  $R_1, R_2, R_3$  and  $R_4$  are independently selected from the group consisting of hydrogen,  $C_{2-6}$  alkyl or alkenyl,  $C_{2-6}$  hydroxyalkyl,  $C_{2-6}$  aminoalkyl, trifluoromethyl,


5 pentafluoroethyl, phenyl, naphthyl, benzyl, biphenyl, phenethyl, piperazinyl, N-methylpiperazinyl, N-ethylpiperazinyl, morpholinyl, piperidinyl, methylpiperidinyl, ethylpiperidinyl, indenyl, 2,3-dihydroindenyl, C<sub>4</sub>-C<sub>7</sub> cycloalkyl or cycloalkenyl, indoyl, methylindoyl, ethylindoyl, or substituted five-membered aromatic heterocyclic rings of the following formulas:




X is defined as above and Z = NH, CH<sub>2</sub>

10

or substituted phenyl rings of the following formulas:



15 X and R' are defined as above.




W = hydrogen, CH<sub>3</sub>, NH<sub>2</sub>, COOR', OR'.

20




Hal = Halogen (F, Cl, etc.).




$X$  and  $R'$  are defined as above.

5 In one aspect of the present invention, there are provided disubstituted triazine dimers in which each triazine monomer is connected to the other by an organic linker wherein said linker contains a 1,3- or 1,4 substituted phenyl group. That is,




10 In such cases, it is possible for  $A = C = 0$  and the phenyl group becomes the linker which connects the two triazine monomers. In such a case, the general formula becomes:




15

This represents one preferred aspect of this invention when  $A = C = 0$  but another preferred embodiment is provided when  $A = -(CH_2)_n-$ , where  $n = 1$  or  $2$  while  $C = 0$ , or  $A = 0$  while  $C = -(CH_2)_n-$  where  $n = 1$  or  $2$ , or  $A = C = -(CH_2)_n-$  where  $n = 1$  or  $2$ . Thus, for example, a preferred aspect of this invention is  $A = -(CH_2)_2-$  and  $C = 0$ , or  $A = 0$  and  $C = -(CH_2)_2-$ . In one preferred case, the general formula becomes:



In an alternative embodiment of the invention, no phenyl group is present in the organic linker which connects the two disubstituted triazine rings, or  $B = 0$ . That is, the triazine dimers are connected by an alkyl chain. Thus, for example, another preferred aspect of this invention is  $A = C \approx -CH_2-$  and  $B = 0$ . Therefore, the organic linker contains a  $-CH_2CH_2-$  or ethylene group and the general formula becomes:



10

Regardless of the organic linker which connects the two triazine rings, it is a preferred embodiment of this invention that  $R_1$ ,  $R_2$ ,  $R_3$  and  $R_4$  are defined as follows:


15

- $R_1$  = hydroxyethyl, hydroxypropyl, hydroxybutyl
- = aminoethyl, aminopropyl, aminobutyl
- = phenyl, anilino, hydroxyphenyl
- $R_2$  = phenethyl, hydroxyphenethyl, aminophenethyl
- =  $R_3$
- $R_4$  = phenyl, anilino, hydroxyphenyl

20

Particularly preferred are the following compounds:


Group 1 compounds where A = —CH<sub>2</sub>—, B = 0, C = —CH<sub>2</sub>— (ethylene linker):

**Compound No.****Structure**


## Compound No.

## Structure


4



5




6




## Compound No.

## Structure


7



8






9





## Compound No.

## Structure

10


11a  
11bX = O  
X = S

12

Group 2 compounds where A =  $-\text{---}(\text{CH}_2)_2\text{---}$ , B = , C = 0or A = 0, B = , C =  $-\text{---}(\text{CH}_2)_2\text{---}$ :

## Compound No.



## Structure




## Compound No.

## Structure


18

19a  
 $X = \text{OH}$ 19b  
 $X = \text{NH}_2$ 


20



21




22




**Compound No.****Structure**

23



24




This invention is, however, not limited to the above two groups of compounds, and other particularly preferred compounds include the following:

5

**Compound No.****Structure**


25




## Compound No.

## Structure


26




27



28




29




## Compound No.

## Structure


30



31




32




## Compound No.

## Structure


33




34



35




36




## Compound No.

## Structure


37




38



39




40




## Compound No.

## Structure


41




42



43




44




## Compound No.

## Structure


45




46




47



48




49



## Compound No.

## Structure



Compounds of the present invention may facilitate the clearance of immune complexes by phagocytosis or may limit the deposition of complexes within body organs and tissues by their ability to antagonize the binding of immune complexes to organ and tissue surfaces. The mechanism by which immune complexes attach to various surfaces can involve binding to cell surface Fc receptors. Fc receptors are glycoproteins of inflammatory leukocytes that bind the Fc (tail) portion of immunoglobulins. Fc receptors are also present on numerous tissues and provide a site for attachment and subsequent deposition of immune complexes onto tissue surfaces. For example, the deposition on kidney tissue of autoantibody containing complexes by binding to Fc receptors is thought to trigger an inflammatory response typical of SLE which can lead to glomerulonephritis. Well characterized Fc receptors include: Fc $\gamma$ RI, Fc $\gamma$ RII and Fc $\gamma$ RIII (IgG receptors); Fc $\epsilon$ RI (the IgE receptor) and Fc $\alpha$ RI (the IgA receptor). Interestingly, Staphylococcal protein A is a cell-surface bacterial protein which can bind to the Fc (tail) portion of most antibodies. For example, protein A will bind to human IgG1, IgG2 and IgG4 immunoglobulins. More importantly, it has been known for many years that protein A can inhibit the binding of IgG antibody containing immune complexes to Fc receptors. For example, A. Sulica *et al.* *Immunology* 38, 173-179 (1979) reported that protein A does inhibit IgG containing immune complex binding to Fc receptors but protein A enhances binding of IgG to lymphocytes and macrophages.

More recently, with the availability of Fc receptor ( $\gamma$  chain) deficient mice, it became possible to establish the primary role of the IgG Fc receptors (Fc $\gamma$ R) in mediating the effector responses seen in autoimmune diseases such as SLE and rheumatoid arthritis, as noted by M. Marino *et al.* *Nature Biotechnology* 18, 735-739 (2000). More specifically, these authors stated that agents which can interfere with the binding of immune complexes to Fc $\gamma$ R should ameliorate SLE. They provided experimental support for this statement by treating a special strain of mice (MRL/lpr) that develops a syndrome which is similar to human SLE with a peptide which binds to the Fc portion of IgG. The survival rate of treated animals (80%) was significantly greater than untreated animals (10%). In a recent review article by P.M. Hogarth *Current Opinion in Immunology* 14, 798-802 (2002), it is stated that Fc $\gamma$ R acts early in the inflammation process and engagement by immune complexes is a potent signal for the release of proinflammatory cytokines such as TNF $\alpha$ . In those cases where compounds of the present invention affect some aspect of immune complex clearance or deposition, they may do so by their ability to mimic protein A. That is, such compounds can bind to the Fc portion of human IgG as ascertained by their ability to inhibit the binding of protein A to human IgG, as determined *in vitro* by competitive ELISA. By binding to the Fc portion of human IgG in a fashion similar to protein A, such protein A mimic compounds may disrupt the binding of IgG containing immune complexes to Fc $\gamma$ R. Subsequently, this should prevent deposition of immune complexes and thereby facilitate their clearance as well as diminish the release of proinflammatory cytokines.

Additionally, or alternatively, compounds of the present invention may inhibit the proinflammatory activity of TNF $\alpha$ . Unlike currently approved recombinant anti-TNF $\alpha$  monoclonal antibodies (Remicade, Humira) or soluble TNF $\alpha$  receptor (Enbrel), compounds of the present invention do not inhibit the binding of TNF $\alpha$  to the p55 TNF $\alpha$  receptor (CD120a) or the p75 TNF $\alpha$  receptor (CD120b). Nonetheless, compounds of the present invention may inhibit the effect of TNF $\alpha$  as ascertained by their ability to inhibit TNF $\alpha$  induced apoptosis/cytotoxicity in the WEHI 164 (13var)

murine cell line. Additionally, compounds of the present invention may inhibit the production of TNF $\alpha$ , as ascertained by their ability to inhibit LPS induced production of TNF $\alpha$  in the J774A.1 murine cell line.

5 TNF $\alpha$  is produced by many cell types which include fibroblasts and numerous immune cell subsets. Examples of the latter include macrophages, monocytes, B and T cells and mast cells. It is a pleiotropic molecule produced in response to a variety of stimuli and which can exert effects on most cell types. Under normal circumstances, low levels of serum TNF $\alpha$  confer protection against pathogens, tumors and tissue 10 damage. Therefore, in terms of chronic or continued use of compounds of the present invention as therapeutic agents, one aspect of this invention may be that these compounds are not potent inhibitors of the effects or production of TNF $\alpha$ , nor do they potently inhibit the binding of TNF $\alpha$  to its receptor. The potential for long-term use of compounds of this invention is demonstrated by the treatment of NZBW/F1 mice 15 (another model for human SLE) with compounds for approximately one year without observation of any significant toxicity.

Similar to biologicals described above, other TNF $\alpha$  inhibitors display toxicity which limits long-term or chronic use. For example, thalidomide (N-phthalimidoglutarimide) is a synthetic anti-inflammatory drug which inhibits TNF $\alpha$  synthesis. But clinical trials for patients with rheumatoid arthritis have been mostly unsuccessful because of unacceptable toxicity. Severe side effects included somnolence, peripheral neuropathy and severe rash. Many drugs that are commonly used as immunosuppressants such as cyclosporin A and methotrexate show TNF $\alpha$  20 inhibitory properties but also cannot be used on a chronic basis because of their toxicity.

Indeed, the pivotal role played by TNF $\alpha$  in many autoimmune diseases, as evidenced by the therapeutic success of recently approved biologicals along with the 30 lack of efficacious yet nontoxic drugs available for chronic treatment, has led to the investigation of a number of approaches for the inhibition of TNF $\alpha$ . Approaches have

included the search for inhibitors of phosphodiesterase IV, agonists of adenosine, matrix metalloproteinase inhibitors (e.g., inhibitors of TACE) signal transduction inhibitors (e.g., p38 MAP kinase) and inhibitors of transcription factors (e.g., NF $\kappa$ B). Clearly then, a need exists for compounds which can efficaciously inhibit the effects of 5 TNF $\alpha$  but which can be used on a long-term basis for the treatment of chronic autoimmune diseases.

The present invention provides novel compounds as defined by the general formula above which are useful for the treatment of chronic autoimmune disease. 10 These compounds may facilitate the clearance of immune complexes by phagocytosis or may limit the deposition of immune complexes within body organs and tissues by their ability to antagonize the binding of immune complexes to organ and tissue surfaces. In this case, such compounds may be particularly useful for the treatment of those autoimmune diseases where immune complexes play an important role in disease 15 pathology: e.g., arthritis, SLE, ITP, glomerulonephritis and vasculitis. Alternatively, the compounds of this invention may inhibit the proinflammatory actions of TNF $\alpha$ . In this case, such compounds may be particularly useful for the treatment of autoimmune diseases where inhibition of biological activity of TNF $\alpha$  is important to disease pathology: e.g., arthritis, psoriatic arthritis, psoriasis, Crohn's disease, inflammatory 20 bowel disease, ankylosing spondylitis, Sjögren's syndrome, Still's disease (macrophage activation syndrome), uveitis, scleroderma, myositis, Reiter's syndrome and Wegener's syndrome. In a preferred embodiment of this invention, these compounds may mimic the activity of bacterial protein A thereby facilitating the clearance of immune complexes and inhibit the biological activity and subsequent effect of TNF $\alpha$ . In any 25 case, it is not intended that the scope of the present invention be limited by the mechanism by which an improvement in any inflammatory condition indicative of an autoimmune disease occurs. Indeed, an improvement in an autoimmune condition may occur by use of compounds of this invention by a poorly defined or unknown mechanism, but said improvement being determined by *in vivo* activity displayed in an 30 appropriate animal model. Therefore, the mechanism(s) by which compound efficacy occurs is not an important nor limiting aspect of this invention. Important, however, is

the fact the compounds of this invention exhibit limited toxicity such that they may be administered accordingly for the treatment of chronic autoimmune disease.

Compounds of the present invention include all pharmaceutically acceptable derivatives, such as salts and prodrug forms thereof, and analogues as well as any geometrical isomers or enantiomers. Formulations of the active compound may be prepared so as to provide a pharmaceutical composition in a form suitable for enteral, mucosal (including sublingual, pulmonary and rectal), parenteral (including intramuscular, intradermal, subcutaneous and intravenous) or topical (including 5 ointments, creams or lotions) administration. In particular, compounds of the present invention may be solubilized in an alcohol or polyol solvent (e.g., solutol HS 15 (polyethylene glycol 660 hydroxystearate from BASF), glycerol, ethanol, etc.) or any other biocompatible solvent such as dimethyl sulfoxide (DMSO) or cremophor EL (also from BASF). The formulation may, where appropriate, be conveniently presented 10 in discrete dosage units and may be prepared by any of the methods well-known in the art of pharmaceutical formulation. All methods include the step of bringing together the active pharmaceutical ingredient with liquid carriers or finely divided solid carriers or both as the need dictates. When appropriate, the above-described formulations may be adapted so as to provide sustained release of the active pharmaceutical ingredient. 15 Sustained release formulations well-known to the art include the use of a bolus injection, continuous infusion, biocompatible polymers or liposomes.

Suitable choices in amounts and timing of doses, formulation, and routes of administration can be made with the goals of achieving a favorable response in the 20 mammal (i.e., efficacy), and avoiding undue toxicity or other harm thereto (i.e., safety). Therefore, "effective" refers to such choices that involve routine manipulation of conditions to achieve a desired effect: e.g., reducing or otherwise ameliorating tissue injury associated with an immune response to body constituents (organs and tissues like adrenal, eye, joint, kidney, liver, lung, pancreas, nervous system, skin, thyroid etc.); 25 restoring the immunological status or normalizing a pathological disorder/condition of the mammal (antibody titer, immune cell subsets, signaling by cytokines or chemokines, antibody-antigen immune complexes etc.); removal of free antibodies

and/or antibody-antigen immune complexes from the circulation; laboratory indicia of autoimmune disease (concentration or absolute amount of soluble mediators of inflammation, presence of autoantibodies, cellular proliferation etc.); and combinations thereof. In particular, deleterious effects of conventional anti-TNF $\alpha$  treatment may be  
5 avoided.

The amount of compound administered is dependent upon factors such as, for example, bioactivity and bioavailability of the compound (e.g., half-life in the body, stability, and metabolism); chemical properties of the compound (e.g., molecular  
10 weight, hydrophobicity, and solubility); route and scheduling of administration; and the like. It will also be understood that the specific dose level to be achieved for any particular patient may depend on a variety of factors, including age, health, medical history, weight, combination with one or more other drugs, and severity of disease.

15 The term "treatment" refers to, *inter alia*, reducing or alleviating one or more symptoms of autoimmune disease in a mammal (e.g., human) affected by disease or at risk for developing disease. For a given patient, improvement in a symptom, its worsening, regression, or progression may be determined by an objective or subjective measure. Treatment may also involve combination with other existing modes of  
20 treatment and agents (e.g., anti-inflammatory drugs, agents binding TNF $\alpha$  like antibody or soluble receptor, NSAIDs, corticosteroids, DMARDs). Thus, combination treatment may be practiced. In such embodiments, it is preferred that toxicity of chronic treatment or the additional agent is at least reduced or avoided by reducing the amount or concentration of the additional agent used in comparison to treatment without a  
25 compound of the present invention.

It will be appreciated by those skilled in the art that the reference herein to treatment extends to prophylaxis as well as therapy of established or chronic autoimmune disease. It will be further appreciated that the amount of a compound of  
30 the invention required for treatment will vary not only with the particular compound used for treatment but also with the route of administration, the nature of the autoimmune condition being treated and the age and general health of the patient. The

dose to be administered will ultimately be at the discretion of the physician. In general, however, the dose will be in the range from about 0.1 mg/kg to about 200 mg/kg of body weight per day. Preferably, doses will range from about 1 mg/kg to about 100 mg/kg of body weight per day. More preferably, the range will be between 2 mg/kg to 5 50 mg/kg of body weight per day.

Finally, and where appropriate, compounds of the present invention may be used in combination with other treatments for autoimmune disease well-known to the art. Other prior art treatments include those described above as represented by 10 nonsteroidal anti-inflammatory drugs (NSAIDs) (e.g., ibuprofen, aspirin, naproxen, etodolac and ketoprofen); corticosteroids (e.g., hydrocortisone, pregnisone and dexamethasone); disease-modifying anti-rheumatic drugs (DMARDs) (e.g., cytotoxic drugs like methotrexate or azathioprine, immunosuppressants like cyclosporin or 15 FK506, hydrochloroquine, organogold salts) and biologicals. The individual components of such combinations may be administered either sequentially or simultaneously in separate or combined pharmaceutical formulations. Alternatively, new pharmaceutical formulations may be created to accommodate the combination of 20 compounds of this invention with conventional treatments for autoimmune disease.

Compounds of the present invention may also be used as affinity agents to bind 25 antibody (e.g., human isotypes like IgM, IgD, IgA1, IgA2, IgE, IgG1, IgG2, IgG3, and/or IgG4) *in vitro* or *ex vivo*. Free (i.e., not bound to antigen) antibody and/or antibody-antigen immune complex may be specifically bound by such affinity agents. Large affinity complexes may be isolated by selective precipitation or differential 30 centrifugation, or identified by flocculation assays. But it is preferred to immobilize one or more compounds to an insoluble support material (e.g., agarose, dextran, cellulose, polyacrylamide, other polymeric materials, silica and glass) preferably covalently linked directly or indirectly by a linker. A compound of the present invention may be synthesized *in situ* on the support or through an activated organic linker. Optionally, the linker may be cleavable (e.g., by a reducing agent or site-specific protease) such that the compound (with or without bound antibody) may be 35 detached from the support. For example, one or more compounds of the present

invention may be covalently linked to a support in the form of a glass slide, multiwell plate, optical fiber, protein chip or test tube for assays and analysis; tissue culture dish for incubating cells or antigen; and magnetic beads, porous membrane or chromatographic media for separation. Antibody or other Fc containing material may 5 be bound to one or more compounds of the present invention (i.e., isolation), and then optionally separated from unbound material (with or without washing and multiple rounds of binding under different conditions) to purify Fc containing material. For example, ionic strength (e.g., salt concentration) or pH may change binding conditions and be used to release Fc containing material.

10

Free antibody and/or immune complexes may be isolated for clinical laboratory diagnosis. Apheresis using standard or fluidized bed chromatography may be used to remove free antibody and/or immune complexes from the circulation: a physiological fluid (e.g., blood) is incubated with insoluble support material on which one or more 15 compounds of the present invention are attached, at least some antibody material is bound to the compound(s) and immobilized on the support, bound antibody is separated from the rest of the physiological fluid, and at least some of the remaining (soluble) components of the physiological fluid is returned to the mammal from whom it was obtained. It is convenient to package the device containing one or more compounds of 20 the invention for apheresis (e.g., a column) under aseptic conditions and to replace it after every use.

Antibody may be isolated from a composition and then optionally separated to any desired degree of purification. An antibody containing composition is incubated 25 with insoluble support material on which one or more compounds of the present invention are attached, and at least some antibody material is bound to the compound(s) and immobilized on the support. Bound antibody may be separated from the remainder of the composition and that remainder is depleted of total antibody or that fraction of antibody which binds (e.g., one or more isotypes). Isolated antibody on the support 30 may be released by washing or cleaving the linker. Either enriched antibody or the components of the depleted composition or both is the desired product. It is convenient

to repeat binding and washing under different incubation conditions to increase the efficiency of isolation and separation.



Therefore, in another embodiment of the present invention, a device or kit is provided for use in the methods described above. For example, it may be used to bind antibody, for isolation of antibody, to remove antibody from a composition or the circulation, for separation of antibody, and to purify antibody from a source material or other composition. The product may be packaged aseptically under pharmaceutically acceptable conditions or stored under sterile conditions for the clinical laboratory. One or more compounds of the present invention are attached to an insoluble support material and packaged in a device (e.g., column) or kit with one or more optional components: storage buffer, binding and washing solutions, and an agent to cleave compounds from the support.

15 EXAMPLES:

The following examples further illustrate the practice of this invention but are not intended to be limiting thereof.

20 The general synthetic sequence for preparation of the compounds useful in the present invention is outlined in schemes I and II. Scheme I illustrates the synthetic route employed for compounds described in this invention except those compounds belonging to Group 2. Also, scheme II demonstrates the synthetic method used for compounds described in this invention except those compounds belonging to Group 1.


SCHEME 1

Method A5 Method B

R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> and R<sub>4</sub> are defined as above.

Reagents: (a) aniline or other arylamine, aq.  $\text{NaHCO}_3$ , acetone/ $\text{H}_2\text{O}$ ,  $0^\circ\text{C}$ ; (b) 2-(4-hydroxyphenyl)ethylamine or other aralkylamine, aq.  $\text{NaHCO}_3$ , THF/acetone/ $\text{H}_2\text{O}$ , room temperature; (c) ethylenediamine, DIEA, THF,  $60^\circ\text{C}$ ; (d) ethylenediamine, aq.  $\text{NaHCO}_3$ , THF/acetone/ $\text{H}_2\text{O}$ , room temperature; (e) 2-(4-hydroxyphenyl)ethylamine or 5 2-(4-hydroxyphenyl)ethylamine derivatives,  $\text{Et}_3\text{N}$ , THF,  $60^\circ\text{C}$ .

## SCHEME 2


Method A

10

$\text{R}_1$ ,  $\text{R}_2$ ,  $\text{R}_3$ ,  $\text{R}_4$ , and  $\text{X}$  are defined as above.

Reagents: (a) aniline or other arylamine, aq.  $\text{NaHCO}_3$ , acetone/ $\text{H}_2\text{O}$ ,  $0^\circ\text{C}$ ; (b) ethanolamine or other alkanolamine, or alkyldiamine, aq.  $\text{NaHCO}_3$ , THF/acetone/ $\text{H}_2\text{O}$ , room temperature;

(c)  $\text{H}_2\text{N}-\text{(CH}_2\text{)}_{0.2}-\text{XH}$ ,  $\text{Et}_3\text{N}$ , THF,  $50^\circ\text{C}$ ; (d)  $\text{R}_4-\text{N}=\text{C}(\text{Cl})=\text{N}-\text{R}_4$ , aq.  $\text{NaHCO}_3$ , THF/acetone/ $\text{H}_2\text{O}$ , room temperature or  $\text{NaH}/\text{THF}$ ; (e)  $\text{R}_3-\text{NH}_2$ ,  $\text{Et}_3\text{N}$ , THF,  $50^\circ\text{C}$ .

Method B (solid phase synthesis):


n = 2-6, X is defined as above

10 Reagents: (a) 1) amine, DCE, RT, 17.5 h, 400 rpm; 2) methanol, DIEA, RT, 1 h, 400 rpm; (b) cyanuric chloride, DIEA, THF, room temperature, 30 min, 400 rpm; (c) 1) for aliphatic amines: amine, DIEA, NMP, room temperature, 20 h, 400 rpm; 2) for aromatic amines: amine, DIEA, NMP, 50°C, 24 h, 400 rpm; (d) amine, DIEA, NMP, 80°C, 20 h, 400 rpm; (e) 5% trifluoroacetic acid/dichloroethane, room temperature, 1 h, 400 rpm.

**Instrumentation:**

All HPLC chromatograms and mass spectra were recorded on a HP 1100 LC-MS Agilent instrument using a diode array detector. An analytical C18 column (250 x 4.6 mm, 5 microns) with a gradient of 10-70% acetonitrile-water containing 0.01% TFA in 10 min and a flow of 1 mL/min (method 1) or an analytical C18 column (75 x 4.6 mm, 5 microns) with a gradient of 10 to 99% acetonitrile-water containing 0.01% TFA in 10 min and a flow of 1 mL/min (method 2) or an analytical C18 column (75 x 4.6 mm, 5 microns) with a gradient of 15-99% acetonitrile-water containing 0.01% TFA in 6 min and a flow of 2 mL/min (method 3) or an analytical C18 column (75 x 4.6 mm, 5 microns) with a gradient of 10-40% acetonitrile-water containing 0.01% TFA in 6 min and a flow of 2 mL/min (method 4) or an analytical C18 column (75 x 4.6 mm, 5 microns) with a gradient of 1-20% acetonitrile-water containing 0.01% TFA in 6 min and a flow of 2 mL/min (method 5).


15

**Example 1 (representative example of scheme I method A): Synthesis of compound 1**

To a suspension of cyanuric chloride (20 g, 108 mmol) in acetone (120 mL) and ice (50 mL) at 0°C was added dropwise a solution of aniline (10 g, 107 mmol) in acetone (45 mL). At the end of the addition, the pH of the solution was adjusted from 1 to 7 with 5% aqueous sodium bicarbonate (150 mL). The precipitate was filtered, washed several times with water and dried *in vacuo*. This gave 2,4-dichloro-6-phenylamino-1,3,5-triazine as an off-white solid (24.3 g, 93% yield). The product was used in the next step without further purification. To a solution of the dichlorotriazine (6.2 g, 25.7 mmol) in THF (300 mL) at room temperature was added a solution of 2-(4-hydroxyphenyl)ethylamine (3.6 g, 25.9 mmol) in acetone (100 mL) and water (100 mL), followed by 5% aqueous sodium bicarbonate (50 mL). After 20 h reaction at room temperature, the solution was diluted with water (50 mL) and ethyl acetate (50 mL). The aqueous layer was extracted with ethyl acetate (2 x 50 mL). The organic layers were washed with brine (150 mL), dried over anhydrous sodium sulphate, filtered and evaporated to dryness. This gave 2-chloro-4-(2-[4-hydroxyphenyl]ethylamino)-6-phenylamino-1,3,5-triazine as an off-white solid (8.5 g, 97% yield). The product was used for the next step without further purification. This triazine derivative (384 mg, 1.1 mmol) was dissolved in THF (11 mL) at room temperature. To this solution was added ethylenediamine (68 µL, 1.0 mmol) followed by diisopropylethylamine (355 µL, 2.0 mmol). After 20 h at 50°C, the solution was diluted with methanol (10 mL) and concentrated under reduced pressure. The crude residue was purified on a Biotage™ 25S column (silica, hexane/AcOEt 9:1 to 0:1) to yield compound 1 as a white solid. Yield of product: 267 mg (78%); <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ 7.63 (m, 4H), 7.21 (t, 4H, *J* = 7.6 Hz), 6.98 (m, 6H), 6.68 (d, 4H, *J* = 7.9 Hz), 3.48 (m, 8H), 2.84 (m, 4H); LRMS (FAB+): *m/z* 672.0 (MH<sup>+</sup>); HRMS: Calc. for MH<sup>+</sup> C<sub>36</sub>H<sub>39</sub>N<sub>12</sub>O<sub>2</sub>, 671.33191; found 671.33060; HPLC (method 1): 8.0 min.

Example 2 (a representative example of scheme II method A): Synthesis of compound

17





To a solution of 2,4-dichloro-6-aminophenyl-1,3,5-triazine (1.6 g, 6.6 mmol) in THF (70 mL) at room temperature was added a solution of ethanolamine (439 mg, 7.3 mmol) in acetone (24 mL) and water (24 mL), followed by 5% aqueous sodium bicarbonate (15 mL). The reaction was stirred for 20 h at room temperature. The mixture was then diluted with water (25 mL) and ethyl acetate (25 mL). The aqueous layer was extracted with ethyl acetate (2 x 25 mL). The organic layer was washed with brine (50 mL), dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure. The crude residue was purified on a Biotage™ 40S column (silica, hexane/AcOEt 9:1 to 0:1) to yield 2-chloro-4-(2-hydroxyethylamino)-6-aminophenyl-1,3,5-triazine as a white solid (1.6 g, 91% yield). This compound (710 mg, 2.7 mmol) was dissolved in THF (26 mL) and 2-(4-aminophenyl)ethylamine (1.1 mL, 8.0 mmol) was added followed by triethylamine (1.1 mL, 8.0 mmol). The reaction was stirred for

20 h at 60°C and then diluted with methanol (20 mL). Solvent was removed under reduced pressure and the crude residue was purified on a Biotage™ 40S column (silica, AcOEt/MeOH 1:0 to 9:1) to yield 2-[2-(4-aminophenyl)ethylamino]-4-(2-hydroxyethylamino)-6-phenylamino-1,3,5-triazine as an off-white solid (916 mg, 91% yield). To a solution of 2,4-dichloro-6-aminophenyl-1,3,5-triazine (356 mg, 1.5 mmol) in THF (30 mL)/acetone (11 mL)/water (11 mL) was added a solution of 1,3,5-triazine derivative above (540 mg, 1.5 mmol) in THF (14 mL) followed by 5% sodium bicarbonate solution (10 mL). The reaction was stirred for 20 h at room temperature and the solution diluted with water (30 mL) and ethyl acetate (30 mL). The aqueous layer was extracted with ethyl acetate (30 mL). The organic layers were washed with brine (40 mL), dried over anhydrous sodium sulphate and filtered. This gave 2-{4-[2-(4-chloro-6-phenylamino-[1,3,5]triazin-2-ylamino)-phenyl]-ethylamino}-6-phenylamino-[1,3,5]triazin-2-ylamino}-ethanol as an off-white solid (860 mg, quantitative yield). The product was used for the next step without further purification.

To a solution of this compound (41 mg, 0.1 mmol) in THF (1 mL) was added 2-(4-aminophenyl)ethylamine (28  $\mu$ L, 0.2 mmol) followed by triethylamine (30  $\mu$ L, 0.2 mmol). After 20 h of reaction at 50°C, the solution was diluted with methanol (5 mL) and concentrated under reduced pressure. The crude residue was purified on a Biotage™ 12M column (silica, AcOEt/MeOH 1:0 to 9:1) to yield compound 17 as a white solid. Yield of product: 30 mg (79%);  $^1$ H NMR (400 MHz, CD<sub>3</sub>OD)  $\delta$  7.63-7.39 (m, 6H), 7.14 (m, 4H), 7.04 (d, 2H,  $J$  = 8.6 Hz), 6.86 (m, 4H), 6.56 (d, 2H,  $J$  = 7.8 Hz), 3.59 (m, 2H), 3.43 (m, 6H), 2.75 (m, 2H), 2.66 (t, 2H,  $J$  = 7.5 Hz); LRMS (ESI): *m/z* 670.2 (MH<sup>+</sup>); HPLC (method 2): 4.3 min.

Example 3 (a representative example of scheme II method B): Solid phase synthesis of compound 16





Reagents: (a) 1) 1,4-diaminobutane, dichloromethane, 17.5 h, 400 rpm; 2) MeOH, DIEA, 25°C, 1 h, 400 rpm; (b) cyanuric chloride, DIEA, THF, 25°C, 30 min., 400 rpm; (c) aniline, DIEA, NMP, 50°C, 24 h, 400 rpm; (d) 2-(4-aminophenyl)ethylamine, NMP, 5 80°C, 20 h, 400 rpm; (e) 2-(4-hydroxyphenyl)ethylamine, DIEA, NMP, 80°C, 20 h, 400 rpm; (f) 5% trifluoroacetic acid/dichloroethane, 25°C, 1 h, 400 rpm.

#### Instrumentation

The solid phase synthesis was performed in Bohdan Miniblocks. They were in sets of 10 two, possessing forty-eight polypropylene reaction tubes. Each tube had a frit at the bottom for filtration of the solid support. A screw acting as a valve allows (or not) the flow of liquids. A heat transfer block surrounding all the tubes was added to provide appropriate heating of the reactions. The heat transfer blocks were coupled to a Julabo FP 40 refrigerated heating circulator. The tubes were covered with a Teflon sheet, 15 rubber septa and closed with the top of the block that contains clips to keep them tightly closed. The blocks were agitated on a modified Innova shaker from New Brunswick Scientific. For evaporation, a Genevac HT-4II was used.

#### Attachment of 1,4-diaminobutane to the 2-chlorotriyl resin for solid phase synthesis

20 In a vial (4.0 mL) was placed resin (53.0 mg, 1.9 mmol) followed by dichloromethane (1.5 mL) and THF (0.5 mL). This mixture was homogenized by use of an automatic pipette. From this mixture, 2.0 mL were placed in the well in a block. By opening the valve, the resin was filtered from the solvent. Dichloromethane (1.0 mL) was then added to wash the resin in each well. The valve was closed and 1,4-diaminobutane (41 25 mg, 0.47 mmol) in dichloromethane (2.0 mL) was added and the block was capped and placed on the shaker for 17.5 h at room temperature and 400 rpm. The blocks were then placed on the vacuum collection set, and the resin filtered by opening the valve. The resin was washed with NMP (2x), methanol (2x), water (3x), methanol (2x), dichloromethane (2x) and THF (1x) respectively.

First addition of cyanuric chloride

The valve was closed and 1.0 mL of a solution of DIEA (68  $\mu$ L, 0.5 mmol) in THF (1 mL) was then dispensed in the well. To this mixture was added 1 mL of a solution of cyanuric chloride (87 mg, 0.5 mmol) in THF (1.0 mL). The blocks were capped with a

5 Teflon sheet and a rubber septum was placed on the shaker and agitated for 30 min at room temperature, 400 rpm. The block was removed from the shaker and placed on a vacuum collection base set. The valve was then opened to filter the resin. THF (1.0 mL) was added to wash the mixture. The valve was closed and more THF (1.0 mL) was added. The block was placed on a shaker for 5 min and the valve opened to filter  
10 the resin. After three washes with THF, a last wash with NMP was undertaken for the next reaction.

Addition of aniline to dichloro-1,3,5-triazine

A solution of DIEA (82  $\mu$ L, 0.5 mmol) in NMP (1.0 mL) was prepared and placed in  
15 the well with the valve closed. To this mixture was added a solution of aniline (43  $\mu$ L, 0.5 mmol) in NMP (1.0 mL). 1.0 mL of this solution was distributed in each well. The blocks were placed on the shaker and agitated for 17.5 h at 50°C at 400 rpm. The blocks were cooled to 25°C and removed from the shaker. The resin was then filtered and washed with NMP (5x) using the same procedure described above.

Addition of the linker to monochloro-1,3,5-triazine

A solution of DIEA (82  $\mu$ L, 0.5 mmol) in NMP (1.0 mL) was prepared and placed in the well with the valve closed. 2-(4-aminophenyl)ethylamine (52  $\mu$ L, 0.4 mmol) was placed in a vial (4.0 mL) and NMP (1.0 mL) was added to give a solution. The blocks  
25 were placed on the shaker and agitated for 18.5 h at 80°C at 400 rpm. After 18 h, the blocks were cooled to 25°C and removed from the shaker. The resins were filtered and washed with NMP (5x), dichloromethane (1x), methanol (1x), dichloromethane (1x), methanol (1x) and dichloromethane (1x) according to the same procedure as described above. By closure of the valve, the blocks were ready for the next step.

Second addition of cyanuric chloride

Same procedure as above.

Second addition of aniline to dichloro-1,3,5-triazine

5 A solution of DIEA (82  $\mu$ L, 0.5 mmol) in NMP (1.0 mL) was prepared and placed in the well with the valve closed. Aniline (43  $\mu$ L, 0.5 mmol) was placed in a vial (4.0 mL) and NMP (1.0 mL) was added. The aniline solution was dispensed in the well. The blocks were placed on the shaker and agitated for 19 h at 50°C at 400 rpm. The blocks were then cooled to 25°C, removed from the shaker and treated according to the same procedure as described previously. The resin was filtered and washed with NMP (5x). By closing the valve, the blocks were ready for the next step.

10

Second addition of 2-(4-hydroxyphenyl)ethylamine to monochloro-1,3,5-triazine

15 A solution of DIEA (82  $\mu$ L, 0.5 mmol) in NMP (1.0 mL) was prepared and placed in the well with the valve closed. 2-(4-Hydroxyphenyl)ethylamine (65 mg, 0.5 mmol) was placed in the vial (4 mL) and NMP (1.0 mL) was added to yield a solution. The 2-(4-hydroxyphenyl)ethylamine solution (1 mL) was distributed in the well and the block was placed on the shaker and agitated for 23 h at 80°C at 400 rpm. The block was cooled to 25°C, removed from the shaker and treated according to the same procedure as described previously. The resin was filtered and washed with NMP (5x), dichloromethane (1x), methanol (1x), dichloromethane (1x), methanol (1x) and 20 dichloromethane (1x) respectively. By closing the valve, the blocks were ready for the next step.

Cleavage of the resin

25 A solution of 5% trifluoroacetic acid in dichloroethane was prepared and 2 mL was added to the well. The blocks were capped, placed on the shaker and agitated for 1 h at room temperature at 400 rpm. Then, the blocks were placed on the vacuum collection base set. The resin was filtered into a clean 96 deep well plate #1. A new clean 96 deep well plate #2 was placed in vacuum collection set. Dichloroethane (1.0 mL) was then added in the well, the valve closed and methanol (1.0 mL) was added. The blocks 30 were agitated on the shaker for 5 min, and filtered into the deep well plate #2. A new clean 96 deep well plate #3 was placed in the vacuum collection set, and methanol (1.0 mL) was added to the well. The 96 deep well plates (1 and 2) were then evaporated in

the Genevac apparatus. Plate #1 was analysed by LC/MS. The plates were combined and placed in the Genevac apparatus and evaporated again. The plates were placed on the HPLC/Gilson for purification. Yellow solid;  $^1\text{H}$  NMR (400 MHz,  $\text{CD}_3\text{OD}$ ):  $\delta$  7.64-6.67 (m, 18H), 3.65 (m, 4H), 3.48 (m, 2H), 2.99-2.79 (m, 6H), 1.72 (m, 4H); LRMS (ESI):  $m/z$  698.2 ( $\text{MH}^+$ ), 720.2 (M+Na); HPLC (method 2): 4.4 min.

5 **Example 4: Synthesis of Compound 2**

The above compound was prepared as in Example 1 starting with methyl anthranilate and 2-(4-hydroxyphenyl)ethylamine. White solid;  $^1\text{H}$  NMR (400 MHz,  $\text{CD}_3\text{OD}$ ):  $\delta$  8.82-6.69 (m, 16H), 3.86 (s, 6H), 3.63-3.49 (m, 8H), 2.73 (s, 4H); LRMS (ESI):  $m/z$  787.2 ( $\text{MH}^+$ ); HPLC (method 1): 8.2 min.

10 **Example 5: Synthesis of Compound 3**

The above compound was prepared by modification of the procedure in Example 1. To 15 a suspension of cyanuric chloride (4 g, 21.7 mmol) in acetone (25 mL) and ice (10 mL) at 0°C was added dropwise a solution of 2-(4-hydroxyphenyl)ethylamine (2.9 g, 21.5 mmol) in THF (15 mL), acetone (10 mL) and water (10 mL). After the end of addition, the pH of the solution was brought from 3 to 7 with a 5% solution of sodium bicarbonate (40 mL). After 2 h of reaction at 0°C, the solution was diluted with water 20 (10 mL) and ethyl acetate (20 mL). The two layers were separated and the aqueous layer was extracted with ethyl acetate (25 mL). The combined organic layers were washed with brine (25 mL), dried over magnesium sulfate, filtered and evaporated to dryness to give a light yellow solid (5.3 g, 86%). The product was used for the next step without further purification. To a solution of this dichlorotriazine (1.21 g, 4.2 25 mmol) in acetone (25 mL) at room temperature was added a solution of ammonia 0.5 M in dioxane (25 mL, 12.7 mmol) and the solution was then stirred at 50°C in a sealed tube for 60 h. The solution was then concentrated under reduced pressure. The crude residue was first purified on a Biotage™ 40M column (silica, hexane/AcOEt 9:1 to 0:1) and then on a semi-preparative HPLC (C18 double-end capped column, 250 x 10 mm, 30 5 microns,  $\text{H}_2\text{O}/\text{CH}_3\text{CN}$  containing 0.05% trifluoroacetic acid 7:3 to 1:9 over 20 min) to yield the chlorotriazine as a white solid (70 mg, 6%).

To a suspension of cyanuric chloride (3 g, 16.3 mmol) in acetone (30 mL) and ice (15 mL) at 0°C was added dropwise a solution of methyl anthranilate (2.46 g, 16.3 mmol) in acetone (10 mL). At the end of the addition, the pH of the solution was brought from 1 to 8.5 with a 5% solution of sodium bicarbonate. After 20 h of reaction at room temperature, the precipitate was filtered off, washed several times with water and dried *in vacuo* to give an off-white solid (4.51g, 93%). The product was used for the next step without further purification. To a solution of this dichlorotriazine (2.0 g, 6.7 mmol) in THF (55 mL) at room temperature was added a solution of 2-(4-hydroxyphenyl)ethylamine (918 mg, 6.7 mmol) in acetone (5 mL) and water (2 mL), followed by a 5% solution of sodium bicarbonate. After 5 h of reaction at 50°C, the solution was diluted with water and ethyl acetate. The aqueous layer was extracted with ethyl acetate (3 x 20 mL). The organic layers were washed with brine (20 mL), dried over sodium sulphate, filtered and evaporated. An off-white solid was obtained (2.45 g, 92%). The product was used for the next step without further purification. To a solution of this chlorotriazine (350 mg, 0.9 mmol) in THF (9 mL) at room temperature was added ethylenediamine (584 µL, 8.7 mmol), followed by triethylamine (1.22 µL, 8.7 mmol). After 20 h of reaction at 55°C, the solution was diluted with methanol (10 mL) and concentrated under reduced pressure. The crude residue was purified on a Biotage™ 25S column (silica, hexane/AcOEt 1:1 to AcOEt/MeOH 3:7) to yield the primary amine as a white solid (227 mg, 62%). To a solution of this amine (37 mg, 87 µmol) in THF (1.5 mL) was added a solution of 2-amino-4-chloro-6-[2-(4-hydroxyphenyl)ethylamino]-1,3,5-triazine (30 mg, 79 µmol) in THF (1.5 mL), followed by diisopropylethylamine (50 µL, 280 µmol). After 48 h of reaction at 50°C, the solution was diluted with methanol (10 mL) and concentrated under reduced pressure. The crude residue was first purified on a Biotage™ 12M column (silica, hexane/AcOEt 8:2 to AcOEt/MeOH 9:1) and then on a semi-preparative HPLC (C18 double-end capped column, 250 x 10 µm, 5 microns, H<sub>2</sub>O/CH<sub>3</sub>CN containing 0.05% trifluoroacetic acid 7:3 to 1:9 over 20 min) to yield compound 3 as a white solid. Yield of product: 17 mg, 33%; <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD): δ 8.60-6.55 (m, 12H), 3.90 (s, 3H), 3.70-3.39 (m, 8H), 2.78-2.66 (m, 4H); LRMS (ESI): *m/z* 653.2 (MH<sup>+</sup>); HPLC (method 1): 4.68 min.

**Example 6: Synthesis of Compound 4**

The above compound was prepared as in Example 1 starting with aniline and *N*-1-*tert*-butyloxycarbonyl-2-(4-aminophenyl)ethylamine. Removal of the Boc group was undertaken using a mixture of HCl/dioxane at room temperature for 3 h. White solid;  
5  $^1\text{H}$  NMR (400 MHz, CD<sub>3</sub>OD):  $\delta$  7.59-7.21 (m, 16H), 3.74-3.69 (m, 4H), 3.25-2.94 (m, 8H); LRMS (ESI): *m/z* 669.4 (MH<sup>+</sup>); HPLC (method 2): 4.2 min.

**Example 7: Synthesis of Compound 5**

The above compound was prepared as in Example 1 starting with *o*-toluidine and 2-(4-10 hydroxyphenyl)ethylamine. White solid;  $^1\text{H}$  NMR (400 MHz, CD<sub>3</sub>OD):  $\delta$  7.11 (m, 2H), 7.02 (m, 4H), 6.97 (m, 6H), 6.66 (d, *J* = 7 Hz, 4H), 3.47 (m, 8H), 2.70 (m, 4H), 2.24 (s, 6H); LRMS (ESI): *m/z* 699 (MH<sup>+</sup>), 721 (M+Na); HPLC (method 2): 4.8 min.

**Example 8: Synthesis of Compound 6**

15 The above compound was prepared as in Example 1 starting with aniline and 4-aminobenzylamine. Light pink solid;  $^1\text{H}$  NMR (400 MHz, CD<sub>3</sub>OD):  $\delta$  7.72-6.61 (m, 18H), 4.39 (s, 4H), 3.55 (m, 4H); LRMS (ESI): *m/z* 663.2 (M+Na); HPLC (method 2): 3.6 min.

**20 Example 9: Synthesis of Compound 7**

The above compound was prepared by modification of the procedure of Example 1. To a suspension of 1,3-phenylenediamine (8.2 g; 75.3 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (21 mL) at 25°C was added dropwise over 1 h a solution of di-*tert*-butylcarbonate (2.7 g, 12.6 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (130 mL). The solution was then stirred at room temperature overnight. After 25 18 h of reaction, the solution was evaporated to dryness under reduced pressure. The residual oil was dissolved in ethyl acetate (50 mL) and washed with a 2 N sodium carbonate solution (50 mL). The aqueous layer was extracted with ethyl acetate (2 x 50 mL). The combined organic layers were washed with brine (50 mL), dried over sodium sulphate, filtered and evaporated to dryness. The crude residue was purified on a 30 Biotage™ 40S column (silica, hexane/AcOEt 95:5 to 1:1) to yield *N*-1-*tert*-butyloxycarbonyl-1,3-phenylenediamine as an off-white solid (2.4 g, 93%). To a suspension of cyanuric chloride (2.2 g, 11.7 mmol) in acetone (15 mL) and ice (6 mL) at

0°C was added dropwise over 15 min, a solution of *N*-1-*tert*-butyloxycarbonyl-1,3-phenylenediamine (2.4 g, 11.6 mmol) in acetone (7 mL). At the end of the addition the pH of the solution was adjusted from 1 to 7 with a 5% solution of sodium bicarbonate (25 mL). The white precipitate was filtered and washed thoroughly with water before being dried under high vacuum. This gave pure 2,4-dichloro-6-(3-*N*-1-*tert*-butyloxycarbonylaminophenyl)amino-1,3,5-triazine as an off-white solid (4.1 g, 99%). The product is used in the next step without further purification. To a solution of this compound (400 mg, 1.12 mmol) in THF (5 mL) at room temperature was added ethylenediamine (38  $\mu$ L, 0.562 mmol), followed by diisopropylethylamine (345  $\mu$ L, 1.97 mmol). After 20 h at 25°C, the solution was diluted with methanol (5 mL) and concentrated under reduced pressure. The crude residue was purified on a Biotage™ 25M column (silica, hexane/AcOEt 8:2 to 4:6) to yield *N*, *N'*-ethylenediamine di[4-chloro-6-(3-*N*-1-*tert*-butyloxycarbonylaminophenyl)-amino-1,3,5-triazine as a white solid (314 mg, 80%). This compound (85 mg, 0.1 mmol) was dissolved in THF (3 mL) at room temperature and added to a solution of 2-(4-aminophenyl)ethylamine (100 mg, 0.7 mmol) in THF (1 mL) followed by triethylamine (102  $\mu$ L, 0.7 mmol). After 20 h at 60°C, the solution was diluted with methanol (2 mL) and concentrated under reduced pressure. The crude residue was purified on a Biotage™ 25S column (silica, hexane/EtOAc 8:2 to 2:8) to yield *N*, *N'*-ethylenediamine di[4-(2-[4-aminophenyl]ethylamino)-6-(3-*N*-*tert*-butyloxycarbonylaminophenyl)amino-1,3,5-triazine] as a white solid (97 mg, 89%). To a solution of this material (97 mg, 0.1 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (1.5 mL) at room temperature was added a solution of 4 N HCl in dioxane (1.5 mL). After 3 h at 25°C, the solution was diluted with 1,2-dichloroethane (10 mL), concentrated under reduced pressure and dried for 20 h under high vacuum. Yellow solid (74 mg, quantitative); <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD):  $\delta$  8.10-7.10 (m, 16H), 3.80-3.60 (m, 8H), 2.99 (m, 4H); LRMS (ESI): *m/z* 699.2 (MH<sup>+</sup>); HPLC (method 2): 2.8 min.

#### Example 10: Synthesis of Compound 8

The above compound was prepared as in Example 1 starting with 2-(4-hydroxyphenyl)ethylamine and L-tyrosine methyl ester. Light pink solid; <sup>1</sup>H NMR

(400 MHz, CD<sub>3</sub>OD):  $\delta$  7.54-6.65 (m, 18H), 4.75 (m, 2H), 3.75-3.40 (m, 14H), 3.18-2.86 (m, 8H); LRMS (ESI): *m/z* 921.2 (MH<sup>+</sup>); HPLC (method 2): 5.1 min.

Example 11: Synthesis of Compound 9

5 The above compound was prepared by saponification of compound 2 using excess lithium hydroxide in a mixture of methanol/water (4:1) at 50°C overnight. Yellow solid; <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD):  $\delta$  9.00-6.50 (m, 16H), 3.70-3.45 (m, 8H), 2.90-2.75 (m, 4H); LRMS (ESI): *m/z* 759.20 (MH<sup>+</sup>); HPLC (method 2): 7.1 min.

10 Example 12: Synthesis of Compound 10

The above compound was prepared as in Example 1 starting with (*R*)-2-phenylglycine methyl ester and 2-(4-hydroxyphenyl)ethylamine. Saponification was undertaken as described in Example 11. White solid; <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD):  $\delta$  7.48-7.32 (m, 10H), 7.05-6.89 (m, 4H), 6.70 (m, 4H), 5.45 (m, 2H), 3.53 (m, 8H), 2.66 (m, 4H); 15 LRMS (ESI): *m/z* 787.2 (MH<sup>+</sup>), 785.2 (M-H); HPLC (method 1): 6.5 min.

Example 13: Synthesis of Compound 11a

20 The above compound was prepared as in Example 1 except aniline was replaced by phenol, sodium bicarbonate by sodium hydride and diisopropylamine by sodium carbonate. White solid; <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD):  $\delta$  7.45-6.95 (m, 12H), 6.80-6.61 (m, 6H), 3.48 (m, 8H), 2.72 (m, 4H); LRMS (ESI): *m/z* 673.2 (MH<sup>+</sup>); HPLC (method 1): 8.4 min.

Example 14: Synthesis of Compound 11b

25 The above compound was prepared as in Example 1 starting with thiophenol and 2-(4-hydroxyphenyl)ethylamine. Pale orange solid; <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD):  $\delta$  7.10-7.64 (m, 10H), 6.40-7.00 (m, 8H), 2.92-3.50 (m, 8H), 2.29-2.70 (m, 10H). LRMS (ESI): *m/z* 705 (MH<sup>+</sup>), 727 (M+Na); HPLC (method 2): 7.9 min.

30 Example 15: Synthesis of Compound 12

The above compound was prepared by coupling compound 1 and 4-(dimethylamino)butyric acid hydrochloride using an excess of 2-chloropyridinium

iodide and triethylamine in DMF at room temperature overnight. The compound was purified on a semi-preparative HPLC (C18 double-end capped column, 250 x 10  $\mu$ m, 5 microns, H<sub>2</sub>O/CH<sub>3</sub>CN containing 0.05% trifluoroacetic acid 4:2 to 3:2 over 25 min). White solid; <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD):  $\delta$  7.52-7.04 (m, 18H), 3.70-3.39 (m, 12H), 5 3.00-2.75 (m, 8H), 2.92 (s, 9H), 2.85 (s, 3H), 2.11 (m, 4H); <sup>19</sup>F NMR (400 MHz, CD<sub>3</sub>OD):  $\delta$  -77.5; quantitative <sup>19</sup>F NMR (400 MHz, CD<sub>3</sub>OD, coaxial insert trifluorotoluene): 8 TFA; LRMS (ESI): *m/z* 897 (MH<sup>+</sup>), 919 (M+Na); HPLC (method 2): 3.8 min.

10 Example 16: Synthesis of Compound 13

The above compound was prepared as in Example 2 except 2-(4-hydroxyphenyl)ethylamine was first added to the 2,4-dichloro-6-phenylamino-1,3,5-triazine followed by adding the linker 2-(4-hydroxyphenyl)ethylamine using sodium hydride instead of sodium bicarbonate. The side chain ethanolamine was replaced by 15 *N*-1-tert-butyloxycarbonylethylenediamine. Removal of the Boc group was undertaken with 5% trifluoroacetic acid in dichloromethane (0°C). White powder; <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD):  $\delta$  7.59 (m, 6H), 7.21 (m, 8H), 7.05 (d, 1H, *J* = 8 Hz), 6.91 (d, 1H, *J* = 8 Hz), 6.71 (d, 1H, *J* = 8 Hz), 6.67 (d, 1H, *J* = 8 Hz), 3.72 (m, 4H), 3.59 (t, 1H, *J* = 8 Hz), 3.39 (m, 1H), 3.22 (m, 2H), 2.97 (m, 2H), 2.80 (t, 1H, *J* = 7 Hz), 2.70 (t, 1H, *J* = 7 Hz); <sup>19</sup>F NMR (300 MHz, CD<sub>3</sub>OD):  $\delta$  -74.8; quantitative <sup>19</sup>F NMR (300 MHz, CD<sub>3</sub>OD, coaxial insert trifluorotoluene): 3 TFA; LRMS (ESI): *m/z* 671 (MH<sup>+</sup>), 654 (M-NH<sub>2</sub>); HPLC (method 2): 4.5 min.

Example 17: Synthesis of Compound 14

25 The above compound was prepared by reacting compound 13 with 1-*H*-pyrazole-1-carboxamidine hydrochloride. Removal of the Boc group was undertaken as described in Example 16. White solid; <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD):  $\delta$  7.56 (m, 4H), 7.37 (m, 4H), 7.21 (m, 6H), 7.03 (d, 1H, *J* = 8 Hz), 6.90 (d, 1H, *J* = 8 Hz), 6.70 (d, 1H, *J* = 8 Hz), 6.65 (d, 1H, *J* = 8 Hz), 3.65 (m, 6H), 3.45 (m, 2H), 2.97 (m, 2H), 2.80 (t, 1H, *J* = 8 Hz), 2.68 (t, 1H, *J* = 8 Hz); <sup>19</sup>F NMR (400 MHz, CD<sub>3</sub>OD):  $\delta$  -77.8; quantitative <sup>19</sup>F NMR (400 MHz, CD<sub>3</sub>OD, coaxial insert trifluorotoluene): 2 TFA; LRMS (ESI): *m/z* 713 (MH<sup>+</sup>), 696 (M-NH<sub>2</sub>); HPLC (method 2): 4.8 min.

**Example 18: Synthesis of Compound 15**

The above compound was prepared as in Example 2 except 2-(4-aminophenyl)ethylamine was first added to the 2,4-dichloro-6-phenylamino-1,3,5-triazine followed by adding the side chain *N*-1-acetyl ethylenediamine. White solid; <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 7.77-7.49 (m, 6H), 7.24 (t, 4H, *J* = 7.9 Hz), 7.12 (d, 2H, *J* = 8.4 Hz), 7.04 (d, 2H, *J* = 8.4 Hz), 6.96 (m, 2H), 6.70 (d, 2H, *J* = 8.4 Hz), 3.66-3.46 (m, 8H), 2.88-2.72 (m, 4H); LRMS (ESI): *m/z* 712.2 (MH<sup>+</sup>); HPLC (method 2): 5.0 min.

10

**Example 19: Synthesis of Compound 18**

The above compound was prepared as in Example 2 except 2-(4-hydroxyphenyl)ethylamine was first added to the 2,4-dichloro-6-phenylamino-1,3,5-triazine followed by 2-(4-aminophenyl)ethylamine. Final substitution on the triazine ring was achieved using *N*-1-*tert*-butyloxycarbonylpiperazine and the removal of the Boc group was undertaken as described in Example 16. Yellow solid; <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 7.58 (m, 6H), 7.39-6.95 (m, 10H), 6.69 (m, 2H), 4.08 (m, 4H), 3.74-3.52 (m, 4H), 2.96-2.75 (m, 4H); LRMS (ESI): *m/z* 696.2 (MH<sup>+</sup>); HPLC (method 2): 4.7 min.

15

**Example 20: Synthesis of Compound 19a**

The above compound was prepared as in Example 2 except aniline was replaced by *N*-1-*tert*-butyloxycarbonyl-1,3-phenylenediamine. Removal of the Boc group was undertaken as described in Example 9. Yellow solid; <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 8.05-7.11 (m, 16H), 3.94-3.48 (m, 8H), 3.00 (m, 4H); LRMS (ESI): *m/z* 700.2 (MH<sup>+</sup>); HPLC (method 2): 3.2 min.

**Example 21: Synthesis of Compound 19b**

The above compound was prepared as in Example 2 except aniline was replaced by *N*-1-*tert*-butyloxycarbonyl-1,3-phenylenediamine and ethanolamine by 1,2-diaminocethane. Removal of the Boc group was undertaken as described in Example 9. Yellow solid; <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 7.00-7.60 (m, 16H), 3.40-3.70 (m, 6H),

20

25

3.00-3.20 (m, 2H), 2.70-2.90 (m, 4H); LRMS (ESI): *m/z* 700 (MH<sup>+</sup>); HPLC (method 3): 1.3 min.

**Example 22: Synthesis of Compound 20**

5 The above compound was prepared as in Example 2 starting with aniline and ethanolamine. 2-(4-aminophenyl)ethylamine was replaced by 2-(4-hydroxyphenyl)ethylamine. Yellow solid; <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD):  $\delta$  7.61 (m, 6H), 7.25 (m, 4H), 7.14 (d, 2H, *J* = 8.5 Hz), 7.07 (d, 2H, *J* = 8.5 Hz), 6.98 (m, 2H), 6.70 (m, 2H), 3.69 (m, 2H), 3.55 (m, 6H), 2.83 (m, 4H); LRMS (ESI): *m/z* 671.2 (MH<sup>+</sup>); HPLC (method 2): 5.1 min.

**Example 23: Synthesis of Compound 21**

10 The above compound was prepared as in Example 16. The side chain ethylenediamine was replaced by ethanolamine. White solid; <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD):  $\delta$  7.58-6.61 (m, 18H), 4.51 (m, 2H), 3.84 (m, 2H), 3.63 (m, 4H), 2.82 (m, 4H); LRMS (ESI): *m/z* 673.2 (MH<sup>+</sup>), 695.2 (M+Na); HPLC (method 2): 9.7 min.

**Example 24: Synthesis of Compound 22**

15 The above compound was prepared using the solid phase procedure described in Example 3 starting with ethylenediamine and 2-methoxyaniline. LRMS (ESI): *m/z* 701.2 (MH<sup>+</sup>), 722.4 (M+Na); HPLC (method 2): 4.2 min.

**Example 25: Synthesis of Compound 23**

20 The above compound was prepared using the solid phase procedure described in Example 3 starting with 1,4-diaminobutane and 2-methoxyaniline. LRMS (ESI): *m/z* 729.2 (MH<sup>+</sup>), 751.2 (M+Na); HPLC (method 2): 4.9 min.

**Example 26: Synthesis of Compound 24**

25 The above compound was prepared using the solid phase procedure described in Example 3 starting with 1,3-diaminopropane and aniline. LRMS (ESI): *m/z* 684.4 (MH<sup>+</sup>), 706.2 (M+Na); HPLC (method 2): 4.4 min.

**Example 27: Synthesis of Compound 25**

The above compound was prepared as in Example 1 except ethylenediamine linker was replaced with 1,3-diaminopropane. White solid;  $^1\text{H}$  NMR (400 MHz,  $\text{CD}_3\text{OD}$ ):  $\delta$  7.72-7.48 (m, 4H), 7.20 (m, 4H), 7.08 (m, 6H), 6.66 (m, 4H), 3.46 (m, 8H), 2.71 (m, 4H), 1.74 (m, 2H); LRMS (ESI):  $m/z$  685.2 ( $\text{MH}^+$ ); HPLC (method 2): 6.0 min.

**Example 28: Synthesis of Compound 26**

The above compound was prepared as in Example 1 except 2-(4-hydroxyphenyl)ethylamine was replaced with ethanolamine and the linker ethylenediamine with 4-aminomethylpiperidine. White solid;  $^1\text{H}$  NMR (400 MHz,  $\text{CD}_3\text{OD}$ ):  $\delta$  7.60 (m, 4H), 7.24 (t, 4H,  $J$  = 7.9 Hz), 6.95 (m, 2H), 3.69 (t, 4H,  $J$  = 5.8 Hz), 3.50 (t, 4H,  $J$  = 5.8 Hz), 3.31 (m, 4H), 2.85 (t, 2H,  $J$  = 12.4 Hz), 1.95 (m, 1H), 1.81 (m, 2H), 1.20 (m, 2H); LRMS (ESI):  $m/z$  573.2 ( $\text{MH}^+$ ); HPLC (method 2): 4.1 min.

15

**Example 29: Synthesis of Compound 27**

The above compound was prepared as in Example 22 except the linker 2-(4-aminophenyl)ethylamine was replaced with 4-aminobenzylamine and the side chain ethanolamine was replaced by histamine. White solid;  $^1\text{H}$  NMR (400 MHz,  $\text{CD}_3\text{OD}$ ):  $\delta$  7.66 (m, 7H), 7.22 (m, 6H), 7.08-6.65 (m, 7H), 4.53 (s, 2H), 3.63 (t, 2H,  $J$  = 7.1 Hz), 3.53 (m, 2H), 2.89 (t, 2H,  $J$  = 7.1 Hz), 2.77 (m, 2H); LRMS (ESI):  $m/z$  707.2 ( $\text{MH}^+$ ); HPLC (method 2): 4.4 min.

**Example 30: Synthesis of Compound 28**

25

The above compound was prepared as in Example 9 except *N*-1-*tert*-butyloxycarbonyl-1,3-phenylenediamine was replaced with aniline, 2-(4-hydroxyphenyl)ethylamine with 2-(4-aminophenyl)ethylamine and the linker ethylenediamine with 1,4-phenylenediamine. White solid;  $^1\text{H}$  NMR (400 MHz,  $\text{CD}_3\text{OD}$ ):  $\delta$  7.72-7.51 (m, 8H), 7.26 (t, 4H,  $J$  = 7.9 Hz), 7.06 (d, 4H,  $J$  = 7.1 Hz), 6.98 (t, 2H,  $J$  = 7.1 Hz), 6.71 (t, 4H,  $J$  = 8.2 Hz), 3.57 (t, 4H,  $J$  = 7.3 Hz), 2.82 (t, 4H,  $J$  = 7.3 Hz); LRMS (ESI):  $m/z$  719.2 ( $\text{MH}^+$ ); HPLC (method 1): 9.0 min.

30

**Example 31: Synthesis of Compound 29**

The above compound was prepared as in Example 1 except aniline was replaced with 5 *N*-1-*tert*-butyloxycarbonyl-1,3-phenylenediamine, 2-[4-hydroxyphenyl]ethylamine with 2-(4-aminophenyl)ethylamine and the linker ethylenediamine with piperazine. Removal of the Boc group was undertaken as described in Example 9. Brown solid;  $^1\text{H}$  NMR (400 MHz, CD<sub>3</sub>OD):  $\delta$  7.46-7.30 (m, 14H), 6.98 (m, 2H), 4.00-3.85 (m, 8H), 3.80-3.75 (m, 4H), 3.01 (m, 4H); LRMS (ESI): *m/z* 725.4 (MH $^+$ ); HPLC (method 2): 3.4 min.

**10 Example 32: Synthesis of Compound 30**

The above compound was prepared as in Example 1 except aniline was replaced with *N*-1-*tert*-butyloxycarbonyl-1,3-phenylenediamine, 2-(4-hydroxyphenyl)ethylamine with 2-(4-aminophenyl)ethylamine and the linker ethylenediamine with 4-aminomethylpiperidine. Removal of the Boc group was undertaken as described in Example 9. Yellow solid;  $^1\text{H}$  NMR (400 MHz, CD<sub>3</sub>OD):  $\delta$  7.78-7.07 (m, 16H), 3.83-3.56 (m, 6H), 3.14-2.92 (m, 8H), 2.17-1.75 (m, 5H); LRMS (ESI): *m/z* 753.4 (MH $^+$ ); HPLC (method 2): 3.2 min.

**Example 33: Synthesis of Compound 31**

20 The above compound was prepared as in Example 1 except aniline was replaced with *N*-1-*tert*-butyloxycarbonyl-1,3-phenylenediamine, 2-(4-hydroxyphenyl)ethylamine with 2-(4-aminophenyl)ethylamine and the linker ethylenediamine with 1,6-diaminohexane. Removal of the Boc group was undertaken as described in Example 9. Yellow solid;  $^1\text{H}$  NMR (400 MHz, CD<sub>3</sub>OD):  $\delta$  7.85-7.06 (m, 16H), 3.74 (m, 4H), 3.48 (m, 4H), 3.01 (m, 4H), 1.68 (m, 4H), 1.47 (m, 2H); LRMS (ESI): *m/z* 755.2 (MH $^+$ ), 777.2 (M+Na); HPLC (method 3): 1.4 min.

**Example 34: Synthesis of Compound 32**

30 The above compound was prepared as in Example 1 except 2-(4-hydroxyphenyl)ethylamine was replaced with 2-(4-aminophenyl)ethylamine and the linker ethylenediamine with 4-aminomethylpiperidine. Yellow solid;  $^1\text{H}$  NMR (400

MHz, CD<sub>3</sub>OD):  $\delta$  7.66-6.74 (m, 18H), 3.64 (m, 4H), 3.09-2.78 (m, 10H), 2.04 (m, 2H), 1.88 (m, 3H); LRMS (ESI): *m/z* 723.2 (MH<sup>+</sup>); HPLC (method 2): 4.1 min.

**Example 35: Synthesis of Compound 33**

5 The above compound was prepared as in Example 2 except the linker 2-(4-aminophenyl)ethylamine was replaced with *N*-1-*tert*-butyloxycarbonylpiperazine. Removal of the Boc group was undertaken as described in Example 16. Light yellow solid; <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD):  $\delta$  7.60 (m, 4H), 7.25 (m, 4H), 6.98 (m, 4H), 6.68 (d, 2H, *J* = 8.2 Hz), 3.83 (m, 8H), 3.70 (t, 2H, *J* = 5.6 Hz), 3.52 (m, 6H), 2.76 (t, 4H, *J* = 6.3 Hz); LRMS (ESI): *m/z* 620.2 (MH<sup>+</sup>); HPLC (method 2): 4.3 min.

10

**Example 36: Synthesis of Compound 34**

The above compound was prepared as in Example 2 except the linker 2-(4-aminophenyl)ethylamine was replaced with 5-amino-2-methylbenzylamine. Light yellow solid. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD):  $\delta$  7.75-6.92 (m, 15H), 6.64 (d, 2H, *J* = 8.0 Hz), 4.52 (s, 2H), 3.68-3.41 (m, 6H), 2.73 (m, 2H), 2.30 (s, 3H); LRMS (ESI): *m/z* 670.2 (MH<sup>+</sup>); HPLC (method 2): 4.4 min.

15

**Example 37: Synthesis of Compound 35**

20 The above compound was prepared as in Example 2 except the linker 2-(4-aminophenyl)ethylamine was replaced with 3-aminobenzylamine. Orange solid; <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD):  $\delta$  7.75-6.64 (m, 18H), 4.37 (s, 2H), 3.77-3.39 (m, 6H), 2.79 (m, 2H); LRMS (ESI): *m/z* 656.2 (MH<sup>+</sup>); HPLC (method 3): 2.4 min.

25 **Example 38: Synthesis of Compound 36**

The above compound was prepared as in Example 1 except 2-(4-hydroxyphenyl)ethylamine was replaced with 2-(4-aminophenyl)ethylamine and the linker ethylenediamine with piperazine. Pink solid; <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD):  $\delta$  7.75-6.68 (m, 18H), 3.98-3.65 (m, 16H), 2.77 (m, 4H); LRMS (ESI): *m/z* 695.2 (MH<sup>+</sup>); HPLC (method 3): 2.2 min.

30

**Example 39: Synthesis of Compound 37**

The above compound was prepared as in Example 2 except ethanolamine was replaced with 2-(4-hydroxyphenyl)ethylamine and the linker 2-(4-aminophenyl)ethylamine with 2-aminobenzylamine. White solid;  $^1\text{H}$  NMR (400 MHz,  $\text{CD}_3\text{OD}$ ):  $\delta$  7.62-6.60 (m, 22H), 4.44-4.38 (m, 2H), 3.53-3.47 (m, 4H), 2.80-2.72 (m, 4H); LRMS (ESI):  $m/z$  733.2 ( $\text{MH}^+$ ); HPLC (method 2): 6.5 min.

**Example 40: Synthesis of Compound 38**

The above compound was prepared as in Example 9 except *N*-1-*tert*-butyloxycarbonyl-

10 1,3-phenylenediamine was replaced with aniline, 2-(4-aminophenyl)ethylamine with 2-(4-hydroxyphenyl)ethylamine and the linker ethylenediamine with 1,3-phenylenediamine. Light yellow solid;  $^1\text{H}$  NMR (400 MHz,  $\text{CD}_3\text{OD}$ ):  $\delta$  7.61 (m, 4H), 7.29-6.92 (m, 14H), 6.69 (d, 4H,  $J$  = 7.4 Hz), 3.52 (t, 4H,  $J$  = 7.2 Hz), 2.79 (t, 4H,  $J$  = 7.2 Hz); LRMS (FAB+):  $m/z$  719.4 ( $\text{MH}^+$ ); LRMS (ESI):  $m/z$  719.2 ( $\text{MH}^+$ ); HPLC  
15 (method 1): 8.6 min.

**Example 41: Synthesis of Compound 39**

The above compound was prepared as in Example 1 except that the monochlorotriazine was treated first with (*R*)-phenylglycinol and triethylamine and the product obtained

20 was treated with sodium hydride. White solid;  $^1\text{H}$  NMR (500 MHz,  $\text{CD}_3\text{OD}$ ):  $\delta$  7.69-6.61 (m, 23 H), 5.15 (m, 1H), 3.96-3.37 (m, 6H), 2.89 (m, 4H); LRMS (ESI):  $m/z$  748.2 ( $\text{MH}^+$ ); HPLC (method 1): 8.8 min.

**Example 42: Synthesis of Compound 40**

25 The above compound was prepared using the solid phase procedure described in Example 3 starting with aniline and ethylenediamine. LRMS (ESI):  $m/z$  670.4 ( $\text{MH}^+$ ), 692.2 ( $\text{M}+\text{Na}$ ); HPLC (method 2): 4.2 min.

**Example 43: Synthesis of Compound 41**

30 The above compound was prepared by method B (scheme 1) starting with *N*-1-*tert*-butyloxycarbonyl-1,3-phenylenediamine and *p*-xylenediamine. 2-(4-hydroxyphenyl)ethylamine was replaced by ammonia gas. Yellow solid;  $^1\text{H}$  NMR (400

MHz, CD<sub>3</sub>OD):  $\delta$  7.83 (m, 2H), 7.69 (m, 2H), 7.41 (m, 6H), 7.12 (m, 2H), 4.63 (m, 4H); <sup>19</sup>F NMR (376MHz, CD<sub>3</sub>OD, coaxial insert trifluorotoluene): 2 TFA; LRMS (ESI): *m/z* 537.4 (MH<sup>+</sup>), 559.2 (M+Na); HPLC (method 5): 4.1 min.

5 Example 44: Synthesis of Compound 42

The above compound was prepared as in Example 2 starting with *N*-1-*tert*-butyloxycarbonyl-1,3-phenylenediamine. 2-(4-aminophenyl)ethylamine was replaced by ethanolamine and the linker 2-(4-aminophenyl)ethylamine with 4-aminobenzylamine. Pale yellow solid; <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD):  $\delta$  8.10-7.87 (m, 1H); 7.86-7.70 (m, 4H); 7.69-7.58 (m, 2H); 7.57-7.40 (m, 5H); 7.20-7.06 (m, 3H); 4.74 (s, 2H); 3.79-3.71 (m, 2H); 3.68-3.56 (m, 2H); LRMS (ESI) *m/z* 658 (MH<sup>+</sup>), 680 (M+Na); HPLC (method 5): 5.7 min.

Example 45: Synthesis of Compound 43

15 The above compound was prepared as in Example 2 starting with *N*-1-*tert*-butyloxycarbonyl-1,3-phenylenediamine. 2-(4-aminophenyl)ethylamine was replaced by ethanolamine and the linker 2-(4-aminophenyl)ethylamine with 3-aminobenzylamine. Pale yellow solid; <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD):  $\delta$  8.06-7.90 (m, 1H); 7.85-7.67 (m, 4H); 7.66-7.57 (m, 2H); 7.56-7.38 (m, 5H); 7.20-7.08 (m, 3H); 4.77 (s, 2H); 3.76-3.72 (m, 2H); 3.68-3.56 (m, 2H); LRMS (ESI) *m/z* 658 (MH<sup>+</sup>), 680 (M+Na); HPLC (method 5): 5.7 min.

Example 46: Synthesis of Compound 44

25 The above compound was prepared as in Example 2 starting with *N*-1-*tert*-butyloxycarbonyl-1,3-phenylenediamine. 2-(4-aminophenyl)ethylamine was replaced by ethanolamine and the linker 2-(4-aminophenyl)ethylamine with piperazine. Off-white solid; <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD):  $\delta$  8.10-7.82 (m, 3H); 7.80-7.65 (m, 2H); 7.63-7.57 (m, 2H); 7.52 (t, *J* = 8.2 Hz, 2H); 7.31-7.19 (m, 1H); 7.11 (d, *J* = 8.0 Hz, 2H); 4.09 (s, 8H); 3.81-3.70 (m, 2H); 3.60-3.53 (m, 2H); LRMS (ESI) *m/z* 622 (MH<sup>+</sup>), 644 (M+Na); HPLC (method 5): 5.9 min.

**Example 47: Synthesis of Compound 45**

The above compound was prepared as in Example 2 starting with *N*-1-*tert*-butyloxycarbonyl-1,3-phenylenediamine and ammonia. 2-(4-aminophenyl)ethylamine was replaced by 3-aminobenzylamine and the linker 2-(4-aminophenyl)ethylamine with 4-aminobenzylamine. Yellow solid;  $^1\text{H}$  NMR (400 MHz,  $\text{CD}_3\text{OD}$ ):  $\delta$  7.85-7.24 (m, 14H), 7.14 (m, 2H), 4.72 (m, 4H); LRMS (ESI):  $m/z$  628.4 ( $\text{MH}^+$ ), 651.2 (M+Na); HPLC (method 4): 2.7 min.

**Example 48: Synthesis of Compound 46**

10 The above compound was prepared by method B (scheme 1) starting with *N*-1-*tert*-butyloxycarbonyl-1,3-phenylenediamine and 1,3-phenylenediamine. 2-(4-hydroxyphenyl)ethylamine was replaced by ethanolamine and ammonia gas. White solid;  $^1\text{H}$  NMR (400 MHz,  $\text{CD}_3\text{OD}$ ):  $\delta$  7.69 (m, 3H), 7.42 (m, 6H), 7.08 (m, 3H), 3.73 (m, 2H), 3.64 (m, 2H); LRMS (ESI):  $m/z$  553.4 ( $\text{MH}^+$ ), 575.6 (M+Na); HPLC (method 15 4): 2.0 min.

**Example 49: Synthesis of Compound 47**

10 The above compound was prepared by method B (scheme 1) starting with *N*-1-*tert*-butyloxycarbonyl-1,3-phenylenediamine and 1,4-phenylenediamine. 2-(4-hydroxyphenyl)ethylamine was replaced by ethanolamine. White solid;  $^1\text{H}$  NMR (400 MHz,  $\text{CD}_3\text{OD}$ ):  $\delta$  7.74 (m, 2H), 7.69 (m, 6H), 7.53 (m, 2H), 7.19 (m, 2H), 3.77 (m, 4H), 3.64 (m, 4H); LRMS (ESI):  $m/z$  597.4 ( $\text{MH}^+$ ), 619.6 (M+Na); HPLC (method 4): 2.3 min.

**Example 50: Synthesis of Compound 48**

10 The above compound was prepared by method B (scheme 1) starting with *N*-1-*tert*-butyloxycarbonyl-1,3-phenylenediamine and *p*-xylenediamine. 2-(4-hydroxyphenyl)ethylamine was replaced by 4-aminobenzylamine. Yellow solid;  $^1\text{H}$  NMR (400 MHz,  $\text{CD}_3\text{OD}$ ):  $\delta$  7.75-7.23 (m, 18H), 7.38 (m, 2H), 4.71 (m, 8H); LRMS (ESI):  $m/z$  747.4 ( $\text{MH}^+$ ); HPLC (method 4): 3.5 min.

**Example 51: Synthesis of Compound 49**

The above compound was prepared by method B (scheme 1) starting with *N*-1-*tert*-butyloxycarbonyl-1,3-phenylenediamine and 1,3-phenylenediamine. 2-(4-hydroxyphenyl)ethylamine was replaced by ethanolamine. White solid;  $^1\text{H}$  NMR (400 MHz,  $\text{CD}_3\text{OD}$ ):  $\delta$  7.71 (m, 3H), 7.48 (m, 6H), 7.11 (m, 3H), 3.74 (m, 4H), 3.65 (m, 4H); LRMS (ESI):  $m/z$  597.2 ( $\text{MH}^+$ ); HPLC (method 4): 2.2 min.

**Example 52: Synthesis of Compound 50**

The above compound was prepared by method B (scheme 1) starting with *N*-1-*tert*-butyloxycarbonyl-1,3-phenylenediamine and 1,3-phenylenediamine. 2-(4-hydroxyphenyl)ethylamine was replaced by serinol. Brown solid;  $^1\text{H}$  NMR (400 MHz,  $\text{CD}_3\text{OD}$ ):  $\delta$  8.20-7.00 (m, 12H), 3.75 (m, 8H), 3.64 (m, 2H); LRMS (ESI):  $m/z$  657.4 ( $\text{MH}^+$ ); HPLC (method 5): 4.5 min.

**Example 53: Synthesis of Compound 51**

The above compound was prepared by method B (scheme 1) starting with *N*-1-*tert*-butyloxycarbonyl-1,3-phenylenediamine and 1,3-phenylenediamine. 2-(4-hydroxyphenyl)ethylamine was replaced by ammonia gas. Off-white solid;  $^1\text{H}$  NMR (400 MHz,  $\text{CD}_3\text{OD}$ ):  $\delta$  7.71 (m, 3H), 7.42 (m, 6H), 7.11 (m, 3H); LRMS (ESI):  $m/z$  509.4 ( $\text{MH}^+$ ), 531.4 (M+Na); HPLC (method 4): 1.7 min.

**Example 54: Ability of Compounds to Mimic Protein A as Determined by Competitive Protein A Binding ELISA**

As described above, this assay evaluates the ability of the exemplified compounds to mimic protein A. Such compounds can bind to the Fc portion of human IgG as ascertained by the inhibition of binding of protein A to human IgG. The competitive protein A binding ELISA assay was performed on a 96-well plate Maxisorp surface to enhance the binding of protein A to the bottom of the plate. The wells were coated with 100  $\mu\text{L}$  of protein A (0.8  $\mu\text{g}$ ) and incubated overnight at 4°C. After incubation, unbound protein A was removed by three washes with phosphate buffer saline (PBS). The plate was then incubated with 100  $\mu\text{L}$ /well of a 2% solution of bovine serum albumin (BSA) for 1 h at 37°C to block non specific protein binding. After incubation,

the plate was washed three times with PBS. 50  $\mu$ L of compound or protein A, diluted in PBS or PBS-20% DMSO at appropriate concentration, were added to the wells followed by addition of 50  $\mu$ L of peroxidase-conjugated human IgG (HRP-IgG). After 1 h incubation at 37°C, the plate was washed three times with PBS to remove unbound HRP-IgG. Bound HRP-IgG was detected by incubation with 100  $\mu$ L of 2,2'-Azino-di[3-ethylbenzthiazoline sulfonate] diammmonium salt crystals (ABTS) solution for 20 min in the dark at room temperature. The plate was then read at 405 nm on a EL 800, universal Microplate reader (Bio-Tek). Data was analyzed in Microsoft Excel and the concentration of compound which inhibits 50% binding of protein A (IC<sub>50</sub>) was calculated using Prism software.

Table 1 represents the IC<sub>50</sub> of compounds tested in the competitive protein A binding ELISA assay, which consists of a side-by-side analysis in PBS and PBS-20% DMSO. DMSO was used to increase the solubility of some of the compounds. These data illustrate the ability of compounds of this invention to inhibit the binding of protein A to the Fc portion of IgG.

Table 1: IC<sub>50</sub> (μM) of protein A mimic compounds as ascertained by ELISA

Compound #	IC <sub>50</sub> (μM): Assay in PBS	IC <sub>50</sub> (μM): Assay in PBS-20% DMSO
1		50
4	44	40
5		36
6	2.4	0.4
7	0.2	0.02
8		28
9		50
10	69	85
11b		45
12	23	39
13	33	70
14	33	63
15		35
16	36	55
17	53	12
18	26	43
19a	0.06	0.003
20		26
21		34
27		28
28		35
29	0.2	0.003
30	0.4	0.03
31	0.99	0.12
32	33	2
33	18	18
34	23	1
35	23	1
36		16
37		23
39		43
41	0.03	0.02
42	0.05	0.05
43	0.08	0.05
44	0.09	0.04
45	0.1	0.08
46	0.2	0.8
47	0.2	0.2
48	0.2	0.05
49	0.3	0.5
50	0.4	1
51	0.6	6

Table 2 summarizes the  $IC_{50}$  of four potent protein A mimic compounds compared to soluble protein A on the competitive ELISA assay. The results further demonstrate the ability of protein A mimic compounds to inhibit the binding of protein A to human IgG.

5 Table 2:  $IC_{50}$  ( $\mu$ M) of four compounds compared to protein A in the competitive ELISA assay

$IC_{50}$ (n = 5 or 6)	Protein A	Compound 19a	Compound 7	Compound 29	Compound 30
PBS	0.187 $\mu$ M	0.088 $\mu$ M	0.187 $\mu$ M	0.225 $\mu$ M	0.426 $\mu$ M
PBS-20% DMSO	0.336 $\mu$ M	0.0035 $\mu$ M	0.0217 $\mu$ M	0.0029 $\mu$ M	0.033 $\mu$ M

Example 55: Effect of Compounds on Phagocytosis of Immune Complexes

This assay was performed to determine the ability of protein A mimic compounds to stimulate or inhibit uptake of FITC-Immune Complex (IC). FITC-IC was prepared by mixing human serum albumin (HSA)-fluorescein isothiocyanate (FITC) with mouse IgG anti-HSA at a 1:4 ratio (four molecules of antibody for one molecule of antigen) on a rotary shaker for 1 h at room temperature. Soluble IC was then incubated with or without compounds or protein A for 10 min. This mixture was added to RAW 264.7 cells and incubated for 2 h at 37°C for IC phagocytosis. After incubation, cells were washed twice in cold PBS (5 min, 1200 rpm) and fixed with 500  $\mu$ L PBS containing 2% formaldehyde. FITC signal taken up by RAW 264.7, which is indicative of IC phagocytosis, was determined by flow cytometry analysis in a Becton Coulter counter with an argon laser and signal was measured through a 530/30nm filter.

20

Figure 1 illustrates a dose-response curve of compound 1 on the phagocytosis of IC with RAW 264.7 (macrophage-like) cells. Results show that phagocytosis of IC is similar to the control at a concentration below 0.4  $\mu$ M of compound 1. An increase in phagocytosis of IC is observed at concentrations of 1, 2 and 4  $\mu$ M, followed by an inhibition at 10 and 20  $\mu$ M (approximately 20%). Phagocytosis of IC was also undertaken with compound 14 and protein A. Phagocytosis of IC is inhibited by compound 14 (approximately 50% at 20  $\mu$ M) and protein A (approximately 50% at 2  $\mu$ M and 20  $\mu$ M).

**Example 56: Effect of Compounds on TNF $\alpha$  Induced Apoptosis in WEHI 13-VAR Cell Line**

Effect of compounds on TNF $\alpha$ -induced apoptosis was measured by a standard biological assay using WEHI-13VAR cells. These cells undergo apoptosis when they

5 are incubated in the presence of TNF $\alpha$  and actinomycin D.  $2 \times 10^4$  WEHI-13VAR cells were incubated in RPMI supplemented with 1% sodium pyruvate and 10% FBS, overnight at 37°C for cell adherence. The cells were then cultured in the presence of 1  $\mu$ g/mL of actinomycin D (to inhibit protein synthesis) and 0.04 nM TNF $\alpha$  with or without compounds at 37°C. After 16-24 h, 50  $\mu$ L of a solution of 2 mg/mL of MTT 10 was added to each well and the plate was then incubated for 4 h at 37°C. Only viable cells metabolize MTT to form formazan salt, which is detectable by the measurement of absorbance at 570 nm. After the incubation, the plate was inverted to remove medium and dead cells. 150  $\mu$ L DMSO was added to each well to stop the reaction and solubilize the formazan salt. Optical density was read on a EL 800, universal 15 Microplate reader (Bio-Tek). A decrease in the optical density is direct evidence of cell apoptosis induced by TNF $\alpha$ . Compounds were also compared to the activity of an anti-TNF $\alpha$  neutralizing antibody. A negative value indicates that the tested compounds, at that particular concentration, were able to stimulate apoptosis.

20 Table 3 represents the percentage of TNF $\alpha$  inhibition (apoptosis) of compounds tested in the cell-based TNF $\alpha$  sensitive WEHI-VAR13 cell proliferation assay. The compounds demonstrated a TNF- $\alpha$  inhibitory activity in the range of 30-50%. In comparison, TNF $\alpha$  antibody demonstrated a TNF $\alpha$  inhibitory activity of 90-95%. This data illustrates the ability of compounds of this invention to inhibit the apoptotic 25 activity of TNF $\alpha$  on TNF $\alpha$  sensitive WEHI-VAR13 cells.

Table 3: Effect of compounds on TNF- $\alpha$  inhibition.

Compound #	WEHI-13VAR assay % inhibition of apoptosis			
	4x10 <sup>-5</sup> M	2x10 <sup>-5</sup> M	1x10 <sup>-5</sup> M	5x10 <sup>-6</sup> M
1	-3.8	17.7	36.8	14.3
2	48.3	48.4	43.7	37.3
3	33.9	44.6	32.7	0.5
4	44.0	25.3	11.2	2.4
5	35.4	38.7	35.1	28.9
12	-30	-28.4	-21.1	36.9
25	-17.8	-0.7	22.8	27.5
26	-11.5	38.0	27.3	9.7
42	30.4	0.5	-1.7	-3.1
45	32.9	4.1	2.9	-0.3

**Example 57: Effect of Compounds on the Binding of TNF $\alpha$  to the p55 TNF $\alpha$  Receptor (CD120a) and the p75 TNF $\alpha$  Receptor (CD 120b)**

Compounds were tested for their ability to bind to TNF $\alpha$  or inhibit the interaction of TNF $\alpha$  with its respective receptors; p55 and p75 TNF $\alpha$  receptor. Three binding ELISA assays were undertaken as described by Mancini *et al.* Biochemical Pharmacology 58, 851-859 (1999). TNF $\alpha$  or receptor (1  $\mu$ g/mL) was coated on a 96-well plate Maxisorp, overnight at 4°C. After incubation, unbound TNF $\alpha$  or p55 TNF $\alpha$  receptor or p75 TNF $\alpha$  receptor was removed and the plate washed three times with PBS. The plate was then incubated with 100  $\mu$ L/well of a 2% BSA solution for 1 h at 37°C to block non specific protein binding. After incubation, the plate was washed three times with PBS. Biotinylated recombinant human TNF $\alpha$  p55 or p75 receptor or biotinylated recombinant human TNF $\alpha$  was added to the wells in the presence or absence of compounds. The plate was incubated for 1 h at 37°C. After incubation, the plate was washed three times with PBS to remove unbound labeled p55 or p75 receptor or recombinant human TNF $\alpha$ . 100  $\mu$ L of avidin-HRP (diluted 1/2000 in PBS-0.1% BSA) was added to each well and incubated 1 h at 37°C. Bound p55 or p75 receptor or recombinant human TNF $\alpha$  was detected by the addition of 200  $\mu$ L of 3, 3',5, 5'-tetramethylbenzidine (TMB) per well for 15 min. The plate was then read at 655 nm on a EL 800 universal Microplate reader (Bio-Tek, Mississauga, Canada). Data was

analyzed in Microsoft Excel and recorded as the percentage of inhibition of p55 or p75 binding to TNF $\alpha$  or TNF $\alpha$  binding to RI (p55) or RII (p75).

Table 4 illustrates the effect of compounds on the inhibition of the direct binding of TNF $\alpha$  RI and RII to TNF $\alpha$  (plastic coated) and TNF $\alpha$  with its receptors (plastic coated). When TNF $\alpha$  is coated on plastic, compounds do not inhibit the binding of RI and RII receptors to TNF $\alpha$ . But when the receptors are coated on plastic, compounds inhibit the binding of TNF $\alpha$  to RII receptor and RI receptor to a lesser extent. The results suggest that inhibition appears not to be due to direct binding of compound to TNF $\alpha$  receptor but instead to TNF $\alpha$ . An inhibition of less than 20% was considered to be insignificant. A negative percentage of inhibition may be due to precipitation or an increase in binding of TNF $\alpha$  to its respective receptors.

Table 4: Effect of compounds on binding of RI or RII or TNF- $\alpha$ .

Compound #	RI and RII Binding assay to TNF				TNF binding assay to TNF RI and RII Receptors			
	% Inhibition of sTNF-R1 binding to TNF- $\alpha$		% Inhibition of sTNF-R2 binding to TNF- $\alpha$		% Inhibition of TNF- $\alpha$ binding to TNF-R1		% Inhibition of TNF- $\alpha$ binding to TNF-R2	
	10 <sup>-4</sup> M	10 <sup>-5</sup> M	10 <sup>-4</sup> M	10 <sup>-5</sup> M	10 <sup>-4</sup> M	10 <sup>-5</sup> M	10 <sup>-4</sup> M	10 <sup>-5</sup> M
1	2.7	0	0	0	46	28.9	63.3	38.4
4	2.19	4.5	5.26	2.06	-69.37	-47.43	-104.77	-86.7
5	1.54	2.95	2.68	4.31	15.4	4.6	38.5	21.2
7					32.6	10.4	36.9	43.3
12					-8.4	-35.7	3.8	-30.4
19a					13.3	-4	27.4	24.3
25	5.65	6.74	4.22	6.76	22.95	3.95	49.25	4.8

15

**Example 58: Effect of Compounds on LPS-Induced TNF $\alpha$  Production in Mouse J774A-1 Cell Line**

Effect of compounds on TNF $\alpha$  production was measured by ELISA using J774-1 cells stimulated by LPS. J774-1 cells were cultured in the presence or absence of LPS and compound. Cells were cultured at 37°C for 24 h and thereafter the supernatants were collected for the determination of the concentration of TNF $\alpha$  by ELISA as recommended by the manufacturer (BD Biosciences). Data was analyzed in Microsoft

Excel and the concentration of compound which inhibits 50% of TNF $\alpha$  production (IC<sub>50</sub>) was calculated using Prism software.

Table 5 summarizes the effect of compounds on TNF $\alpha$  production induced by LPS on J774-1 cells.

Table 5: Effect of compounds on the inhibition of TNF $\alpha$  released by LPS induction from J774A.1 cells.

Compound #	IC <sub>50</sub> ( $\mu$ M)
1	9.2
3	28.0
4	94.4
5	44.0
11a	45
11b	23.3
12	3.4
13	13.4
14	11.8
15	14.2
16	13.6
17	57.1

Compound #	IC <sub>50</sub> ( $\mu$ M)
18	10.2
19a	20.7
20	23.3
21	4.8
22	62.1
23	16.5
24	11.5
25	15.9
28	28.8
33	20.6
38	9.5
40	87.2

Example 59: Effect of Protein A Mimic Compounds on Peripheral Blood Mononuclear Leukocytes (PBML) Cells Cytotoxicity, DNA, RNA and Protein Synthesis.

PBML were obtained from the peripheral blood of healthy volunteers. Blood was submitted to gradient centrifugation with Lympholyte-poly (Cedarlane, Hornby, Canada). The layer, which contains the mononuclear leukocytes, was collected and the cells washed three times in PBS. Cells were then suspended in RPMI (Gibco, Burlington, Canada) supplemented with 10% FBS (Hyclone, Logan USA). Viability was greater than 99% as determined by trypan blue exclusion.

PBML were resuspended at 2 x 10<sup>6</sup> cells/mL. 100  $\mu$ L of PBML (2 x 10<sup>5</sup> cells) were incubated in a 96-well microtiter plate for 48 h in the presence or absence of compound or protein A. Cells were quiescent or stimulated with concanavalin A (ConA; T-cells) or pokeweed mitogen (PWM; B-cells). After incubation, cells were treated with MTT

(cytotoxicity) or pulsed with 1  $\mu$ Ci of [ $^3$ H]-thymidine (DNA synthesis), [ $^3$ H]-uridine (RNA synthesis) or [ $^3$ H]-leucine (protein synthesis) for 6 h. Plates were harvested on a Tomteck and counted on a Microbeta  $\beta$ -counter.

5 Table 6 summarizes the effect of protein A mimic compounds on cell cytotoxicity, DNA, RNA and protein synthesis in comparison with protein A on PBML. Protein A has no effect on DNA, RNA and protein synthesis. Furthermore, it does not induce cell cytotoxicity. Cell cytotoxicity was observed only on PBML stimulated with Con A, a mitogen stimulating T-cell proliferation. No cytotoxic effect was observed in resting 10 PBML. PWM, a mitogen stimulating B-cell proliferation, stimulation is not affected by the protein A mimic compounds. Furthermore, compound 1, 7 and 19a suppress DNA and RNA synthesis in both resting and stimulated (ConA and PWM) PBML. Only compound 1 and 19a, however, inhibit protein synthesis in resting and stimulated PBML. These results suggest a suppression of both T and B cells. These cells are 15 strongly implicated in autoimmune diseases.

Table 6: Effect of protein A mimic compounds on resting and stimulated PBML cytotoxicity, DNA, RNA and protein synthesis.

Compound #	PBML (IC <sub>50</sub> Results in $\mu$ M)											
	Cytotoxicity			DNA Synthesis			RNA Synthesis			Protein Synthesis		
	Resting	ConA	PWM	Resting	ConA	PWM	Resting	ConA	PWM	Resting	ConA	PWM
	IC <sub>50</sub>	IC <sub>50</sub>	IC <sub>50</sub>	IC <sub>50</sub>	IC <sub>50</sub>	IC <sub>50</sub>	IC <sub>50</sub>	IC <sub>50</sub>	IC <sub>50</sub>	IC <sub>50</sub>	IC <sub>50</sub>	IC <sub>50</sub>
Protein A	>20	>20	>20	*	>20	>20	*	>20	>20	>20	*	*
1	>10	8.7	>10	2.49	1.42	0.77	1.1	0.92	0.66	6.48	2.44	2.96
7	>10	>10	>10	3.6	3.52	1.28	1.12	1.5	1.78	>10	>10	>10
19a	10	6.8	>10	1.9	1.57	4.38	0.399	0.693	0.398	9.9	3.91	4.88

\*Increase

20

Example 60: Effect of Compounds on Systemic Lupus Erythematosus (SLE)-Glomerulonephritis

New Zealand mice of the F1 hybrid cross NZBxNZW develop most of the autoimmune abnormalities seen in human SLE and die from SLE-like immune complex (IC)-mediated glomerulonephritis. The mice develop high titers of anti-DNA (double-strand and single-strand) and nuclear extract (NE) antibodies, as well as SLE-related clinical manifestations including leukopenia, thrombocytopenia, proteinuria and

glomerulonephritis. These mice develop anti-DNA antibodies after the age of 3 months, with a peak of anti-DNA antibody response occurring at 7 months. Subsequently, the serum concentration of anti-DNA antibodies declines, presumably as a consequence of progressive uremia. The first serological manifestations of the disease occurs at about 150 days (5 months). Their survival is evaluated at approximately 250 days.

Figure 2 illustrates the effect of compound 1 on the mortality of the NZBxNZW mice. Intravenous administration of compound or vehicle was undertaken once a week from week 18 to week 37. Treatment ceased for 11 weeks and was restarted at week 48 for the control and compound 1 groups. Results indicate that compound 1 reduces the mortality of NZBxNZW mice at week 37. It also delays the appearance of symptoms and mortality up to week 45. Figure 3 illustrates the proteinuria at week 48 to 51. The amount of protein greater than 5g/liter in the compound 1-treated mice was greater than the control due to the kinetics of the disease (exponential phase).

But with the continuation of treatment at week 48 to week 52 using weekly intravenous administration of the vehicle or compound, compound 1 induces a decrease in protein concentration (5 g/liter) in urine compared to the vehicle alone (Fig. 3A). Furthermore, an increase in trace amount of protein in urine is observed in mice treated with compound 1 (Fig. 3B) indicating an improvement in kidney filtration.

The results of a second SLE are presented in Figure 4. Compounds delay the mortality, as seen by an increase in survival of NZBxNZW mice. Compounds 1 and 9 increase the survival up to 35% compared to the control group. Furthermore, compound 1 extended survival up to 89 weeks compared to 65 weeks for control.

Figure 5 is an example of the effect of compounds on survival of MRL/lpr mice. These mice also spontaneously develop SLE-like syndrome. MRL/lpr have a homozygous fas mutation, which accelerates autoimmunity. Compounds delay the mortality as seen by an increase in survival of MRL/lpr mice. Furthermore, compounds 1 and 20 increase the survival (40%) compared to the control group (10%).

Example 61: Effect of Compounds on Oxazolone-Induced Delayed-Type Hypersensitivity (DTH)

Compounds were tested for their ability to treat oxazolone-induced delayed-type hypersensitivity (DTH) in mice. On day 0, mice were sensitized with 100  $\mu$ L of oxazolone in 5% acetone. On day 0, 1 and 2, mice were treated by intravenous or oral administrations of the vehicle (control) or methotrexate (MTX; positive control/IV) or hydrocortisone (positive control/PO) or the compound at 50 mg/kg to 300 mg/kg of body weight. Mice were challenged with an application of 50  $\mu$ L of oxazolone on the surface of the right ear (first challenge, day 3; second challenge, day 10). Ear thickness was measured on day 4 to day 7, and on day 11 to 14. Redness and crust formation was also observed. Mice were sacrificed on day 14. T<sub>DTH</sub> (CD4) cells play an important role in regulating the intensity of the DTH response. Compounds may exert an inhibitory influence on the DTH response through its inhibition of T-cell activation and DNA, RNA and/or protein synthesis.

As illustrated in Figures 6 and 7, all compounds induce a significant reduction of the inflammation as seen by lower ear thickness. Also, compound 19a alone is equipotent to methotrexate. Compounds also reduce redness, crust formation and ear swelling.

As illustrated in Figure 8, when administered orally at day 0, 1 and 2, compounds 1 and 19a induce a significant reduction of the inflammation as seen by lower ear thickness. Also, compounds 1 and 19a alone are equipotent to hydrocortisone at concentrations of 150 mg/kg (compound 1) and 300 mg/kg (compounds 1 and 19a) of body weight. Compounds also reduce redness, crust formation and ear swelling.

Example 62: Effect of Compounds on Collagen-Induced Arthritis

Collagen-induced arthritis (CIA) was induced in female Lewis rats by intradermal administration of heterologous (bovine) type II collagen (250  $\mu$ g) solubilized in 0.1M acetic acid and emulsified in Complete Freund's Adjuvant (CFA). Rats were treated with the vehicle or methotrexate or compound 1 by intravenous injections at day 8, 9, 12, 14 and 16. Synovitis typically develops 12-15 days postimmunization in 80-90% of

the animals. Once arthritis appears, each paw was examined two to three times a week. Both the incidence and severity of the arthritis was evaluated. Incidence is defined as the number of rats with clinical evidence of joint inflammation during the study period while severity was quantified by scoring daily each paw integer on a scale of 0 to 4 (0=normal, 4=maximum; Table 7) based on increasing levels of swelling, periarticular erythema and stiffness. The sum of the scores for all four paws was calculated as the arthritic index with a maximum possible score of 16 per rat. Since CIA primarily affects hind limbs, scores of 6-8 represent severe arthritis.

10 Table 7: Definition of severity score for CIA and AIA rat arthritis models

Severity Score	Gross Pathology
0	No evidence of erythema and swelling
1	Erythema and mild swelling confined to the mid-foot (tarsals) or ankle joint
2	Erythema and mild swelling extending from the ankle to the mid-foot
3	Erythema and moderate swelling extending from the ankle to the metatarsal joints
4	Erythema and severe swelling encompass the ankle, foot and digits

15 As illustrated in Figure 9, 80-90% of the animals developed a severe synovitis after 12-15 days postimmunization. Inflammation reaches its maximum at day 16. A significant reduction (50%) in the severity of arthritis (arthritic index) was observed by intravenous injection of methotrexate (positive control) by day 14 and beyond. A weaker but significant reduction (20%) of the arthritic index was also observed with compound 1 from day 16 to day 21.

20 Example 63: Effect of Compounds on Freund's Adjuvant-Induced Arthritis (AIA)

25 AIA was induced in female Lewis rats by the injection of lyophilized *Mycobacterium butyricum* suspended in mineral oil into the footpad. The development of arthritis was monitored over a 3 weeks period post-adjuvant injection. Inflammation peaks at day 3 following the adjuvant administration. Immune activation appears around day 14. Compounds were orally or intravenously administered at different doses at day -3, -2 and -1 pre-adjuvant injection and at different regimen as specified in the experiment

starting from day 10 through 21 post-adjuvant injection or animals were treated with oral administration of compound **19a** from day -3 to day 21. Body weight was recorded. The arthritis index, which is a measure of inflammation (oedema), redness and stiffness of the articulations, was used to monitor the development of the disease.

5 The degree of arthritis was determined by measuring two perpendicular diameters of the ankles in the mediolateral and dorsoventral planes using a caliper. Joint circumference in millimeters is then calculated using a geometric formula. Both the incidence and severity of the arthritis was evaluated. Incidence is defined as the number of rats with clinical evidence of joint inflammation during the study period.

10

As illustrated in Figure 10, 100% of the animals rapidly developed a synovitis. Inflammation reaches its maximum at day 3 postimmunization. Animals were treated by intravenous administration of compounds on days -3, -2, -1, 12, 13, 14, 18, 19 and 20. A significant reduction (50%) in the severity of arthritis (inflammatory index) was 15 observed by intravenous injection of methotrexate (positive control) by day 19 and over. A weak but still significant reduction (20%) of the inflammatory index was also observed with compounds **1** and **19a** from day 3 to day 5.

Furthermore in Figure 11, a significant reduction (up to 50%) in the severity of arthritis 20 (inflammatory index) was observed by intravenous injections (days -3, -2, -1, 11, 12 and 13) of compounds **1** and **19a** on acute inflammation (days 1 to 6). Also, a significant inhibition of inflammation was observed upon oral administration of compound **19a** on acute inflammation compared to the control and methotrexate. A 25 strong and significant inhibition of inflammation was also observed on chronic inflammation (days 12 to 21) by compound **19a** (IV; days 12 to 19, PO; day 16) and methotrexate (days 15 to 21).

When compound **19a** was orally administered every day (days -3 to 21), a significant 30 inhibition (up to 50%) of inflammation was observed from day 13 through day 22 (Figure 12).

**Example 64: Use of Compounds to Bind and Purify Immunoglobulins**

As noted above, exemplified compounds may be used as affinity agents to bind antibody and subsequently isolate and purify the antibody from a mixture of proteins.

Such purification is conveniently accomplished when the compound is first covalently

5 linked, either directly or by a linker, to an insoluble support material. Thus, 101 g of epoxide activated cross-linked (with epichlorohydrin) 6% agarose beads were treated

with a solution of 6-aminohexanoic acid (8.0 g, 61 mmol) in water (101 mL) and the slurry was adjusted to pH = 12 with 2 M NaOH. The reaction was shaken on a rocker plate for 44 h. The beads were filtered, washed with water (5 x 100 mL), then

10 resuspended in water (100 mL) and treated with a solution of sodium borohydride (202 mg, 5.34 mmol) in 10 M NaOH (20 mL). The reaction was shaken on a rocker plate for 25 h. The beads were filtered, washed with water (11 x 200 mL) until the pH of the

filtrate was neutral and a sample of the gel was freeze-dried for elemental analysis: C 47.366%; H 6.966%; N 0.990%. Based on one atom of nitrogen per molecule of 6-

15 amino hexanoic acid, this corresponds to a loading of 707 micromol/g freeze dried gel. The settled gel (4 g) was treated with a solution of compound 19b (275 mg, 0.30 mmol) in water adjusted to pH = 4.5 (3.0 mL). A solution of 1-[3-(dimethylamino)propyl]-3-

ethylcarbodiimide hydrochloride (400 mg, 2.09 mmol) in water adjusted to pH = 4.5 (3.0 mL) was added to the reaction which was then shaken on a rocker plate for 21 h.

20 The slurry was filtered, washed with 0.1M HCl (3 x 10 mL) and water (10 x 8 mL) to yield a pale brown gel. The packed gel (200  $\mu$ L in a spin column) was equilibrated in 20 mM PBS (pH = 7). In this format, the exemplified compound immobilized to a solid support may be used for purification of antibody.

25 Solid phase binding evaluates the exemplified compounds for their ability to bind, remove, and/or purify immunoglobulins. Exemplified compounds were linked either directly or with an organic linker to an insoluble support material (resin). The gel

(exemplified compound linked to the resin) was packed on a spin column. 200  $\mu$ L of packed gel was equilibrated in 20 mM sodium phosphate buffer (pH = 7). Total human

30 IgG (Sigma, St. Louis, USA; purified human IgG isolated from pooled normal human serum) (see lane 2 of Fig. 13) was introduced through the gel and flow through (see lane 3 of Fig. 13) was collected. The gel was washed with five-column volumes of 20

5 mM sodium phosphate buffer (pH = 7) plus 0.25M NaCl. Wash fractions (see lane 4 of Fig. 13) were collected. Bound IgGs were eluted at low pH with 0.1M citric acid (pH = 3). Eluted IgG (see lane 5 of Fig. 13) was collected and then neutralized with Tris HCl (pH = 8). SDS-PAGE (12%) of collected fractions was performed and proteins were visualized using Coomassie blue staining. As represented in Figure 13, up to 80% of human total IgG was bound and purified when compound 19b was linked to resin by an aminohexanoic acid linker.

10 Patents, patent applications, and other publications cited herein are incorporated by reference in their entirety.

15 All modifications and substitutions that come within the meaning of the claims and the range of their legal equivalents are to be embraced within their scope. A claim using the transition "comprising" allows the inclusion of other elements to be within the scope of the claim; the invention is also described by such claims using the transitional phrase "consisting essentially of" (i.e., allowing the inclusion of other elements to be within the scope of the claim if they do not materially affect operation of the invention) and the transition "consisting" (i.e., allowing only the elements listed in the claim other than impurities or inconsequential activities which are ordinarily 20 associated with the invention) instead of the "comprising" term. Any of the three transitions can be used to claim the invention.

25 It should be understood that an element described in this specification should not be construed as a limitation of the claimed invention unless it is explicitly recited in the claims. Thus, the claims are the basis for determining the scope of legal protection granted instead of a limitation from the specification which is read into the claims. In contradistinction, the prior art is explicitly excluded from the invention to the extent of specific embodiments that would anticipate the claimed invention or destroy novelty.

30 Moreover, no particular relationship between or among limitations of a claim is intended unless such relationship is explicitly recited in the claim (e.g., the arrangement of components in a product claim or order of steps in a method claim is not a limitation


of the claim unless explicitly stated to be so). All possible combinations and permutations of the individual elements disclosed herein are considered to be aspects of the invention; similarly, generalizations of the invention's description are considered to be part of the invention.

5

From the foregoing, it would be apparent to a person of skill in this art that the invention can be embodied in other specific forms without departing from its spirit or essential characteristics. The described embodiments should be considered only as illustrative, not restrictive, because the scope of the legal protection provided for the 10 invention will be indicated by the appended claims rather than by this specification.

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:-


1. A compound of the following formula:



where  $A = -(CH_2)_n-$    $n = 0-2$ , or  
 $= -(CH_2)_m-$  ;  $m = 2-4$   
 $X = H$  or  $NH_2$

5


wherein  $R_1$ ,  $R_2$ , and  $R_3$  are independently selected from the group consisting of



10

$C_{2-4}$  aminoalkyl, benzyl, and  $C_{2-4}$  hydroxyalkyl.

2. The compound according to claim 1, wherein:




15

$n = 0, 1$  or  $2$ .


3. The compound according to claim 2, wherein:

$R_1$  and  $R_2$  are selected from the group consisting of aminoethyl, hydroxyethyl, and



20

4. The compound according to claim 3, wherein  $R_1$  is hydroxyethyl and  $R_2$  is




5. A compound selected from the group consisting of:


**Compound No.**

**Structure**


1





2





3













81


21




22




23








24



25









84


34




35




36




37




38




39




40



41




42




86


43




44




45




46




47




48




49



50




51



6. The compound according to any one of claims 1 to 5, wherein said compound binds noncovalently to antibodies.

7. The compound according to claim 1, wherein one, two, three or all of the  
5 substituents  $R_1, R_2, R_3$  is



8. The compound according to claim 6, wherein the antibodies are at least of the human IgG isotype.

9. A pharmaceutical composition comprising of at least one compound according to any one of claims 1 to 8, and a pharmaceutically acceptable carrier.
10. The pharmaceutical composition according to claim 9, wherein said compound is solubilized in an alcohol.
- 5 11. The pharmaceutical composition according to claim 9 or 10, said pharmaceutical composition further comprising a recombinant protein which binds to human TNF $\alpha$ .
12. The pharmaceutical composition according to claim 11, wherein said recombinant protein is an anti-TNF $\alpha$  antibody or a soluble TNF $\alpha$  receptor.
- 10 13. The pharmaceutical composition according to any one of claims 9 to 12, said pharmaceutical composition further comprising methotrexate.
14. The pharmaceutical composition according to any one of claims 9 to 13, said pharmaceutical composition further comprising an anti-inflammatory corticosteroid.
- 15 15. The pharmaceutical composition according any one of claims 9 to 14, said pharmaceutical composition further comprising of a nonsteroidal anti-inflammatory drug.
16. Method for treating a patient with glomerulonephritis, psoriasis, rheumatoid arthritis, and/or systemic lupus erythematosus comprising administering to said patient a therapeutically effective amount of a compound according to any one of claims 1 to 8 or a pharmaceutical composition according to any one of claims 9 to 15.
- 20 17. The method according to claim 16, further comprises the administration to said patient of methotrexate, an anti-inflammatory corticosteroid, and/or a nonsteroidal anti-inflammatory drug.
18. The method according to claim 16 or 17, wherein therapeutically effective amount of a recombinant protein which binds to human TNF $\alpha$  is administered to said patient simultaneously with a compound of any one of claims 1 to 8 and wherein said therapeutically effective amount of recombinant protein is reduced in the presence of said compound.
- 25 19. Use of a compound according to any one of claims 1 to 8, for the manufacture of a medicament for treating a patient with glomerulonephritis, psoriasis, rheumatoid arthritis, and/or systemic lupus erythematosus.

20. The use according to claim 19, wherein said medicament further comprises methotrexate, an anti-inflammatory corticosteroid, and/or a nonsteroidal anti-inflammatory drug.
21. The use according to claim 19 or 20, wherein said medicament is for 5 simultaneous administration with a therapeutically effective amount of a recombinant protein which binds to human TNF $\alpha$ , and wherein said therapeutically effective amount of recombinant protein is reduced in the presence of said compound.
22. A method of removal of human antibodies, comprising circulating blood or other physiological fluid through an apheresis column, wherein at least one compound 10 according to any one of claims 1 to 8 is covalently linked either directly or indirectly with an organic linker to an insoluble support material which constitutes part of said apheresis column, such that at least some free antibodies and/or antibody-antigen immune complexes binds to the apheresis column.
23. A method of purification of antibodies, comprising:
  - 15 - providing an insoluble support material to which at least one compound according to any one of claims 1 to 8 is covalently linked either directly or indirectly with an organic linker;
  - contacting antibodies with said at least one of said compound covalently linked to the insoluble support material, whereby at least some antibodies binds 20 noncovalently to said at least one compound; and
  - purifying the noncovalently bound antibodies.
24. An *in vitro* method of binding antibodies using at least one compound according to any one of claims 1 to 8, comprising incubating said at least one compound with antibodies under binding conditions, and then separating bound antibodies from free 25 antibodies.
25. A compound according to claim 1 or 5; or a pharmaceutical composition according to claim 9; or a method according to any one of claims 16, 22 or 23; or use according to claim 19; or an *in vitro* method according to claim 24, substantially as herein described with reference to any one of the embodiments of the invention 30 illustrated in the accompanying drawings and/or examples.

1/7




Fig. 1




Fig. 2

2/7




Fig. 3A




Fig. 3B




Fig. 5

3/7




Fig. 4

4/7




Fig. 6




Fig. 7

5/7





Fig. 8



\*MTX is significantly different from control for the rest of the protocol.

\*\*Compound 1 is significantly different from the control.

Fig. 9

6/7




Fig. 10




Fig. 11

7/7




Fig. 12




Fig. 13